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ABSTRACT
This work tested the hypothesis that oxidation of methionine 388 in thrombomodulin is
higher in cigarette smokers, and thus a likely contributor towards the hypercoagulable state in
smokers. Thrombomodulin, a protein cofactor found on endothelial cell surfaces, regulates the
activity of thrombin. Thrombin bound to thrombomodulin no longer converts fibrinogen to
fibrin, but instead activates Protein C which, in turn, stops the coagulation cascade by
inactivation of clotting factors. The oxidation of methionine 388 of thrombomodulin has been
shown in vitro to dramatically decrease the anticoagulant cofactor activity of thrombomodulin.
The blood of cigarette smokers is more prone to clot than that of non-smokers, a major factor in
their premature deaths from cardiovascular disease. Cigarette smoke consists of many oxidizing
species that impose oxidative stress on the body. These species include organic radicals and
hydrogen peroxide, which can oxidize methionine. The fact that smokers are in a
hypercoagulable state has been established, however the molecular origins of such a state have
not been elucidated. Techniques were developed to isolate thrombomodulin cleared from the
blood stream in urine, proteolytically digest it, and identify using mass spectrometry the peptide
containing methionine 388 in both its oxidized and reduced forms. In many cases the oxidized
version of the peptide was below the limits of detection in non-smokers and the reduced version
was not detected in smokers. The intensity of these peaks in the mass spectra do not allow
calculation of absolute percentages of oxidation because of differences in proton affinity of the
two forms, but there is a very statistically significant difference (P=0.002 by Mann-Whitney
Rank Sum test) in the apparent median reduced to oxidized ratios of >2.043 for non-smokers and
of <0.308 for smokers. The much greater degree of oxidation of thrombomodulin methionine
388 in smokers should be examined for its contribution to smoking morbidity and mortality.
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CHAPTER 1: DOES THE OXIDATION OF METHIONINE 388 IN THROMBOMODULIN
CONTRIBUTE TOWARDS THE HYPERCOAGUABLE STATE IN CIGARETTE
SMOKERS?

1

General introduction
Proteins are susceptible to oxidation and there are several consequences of that.
Oxidation can lead to modification of side chain properties, dimerization of the protein,
conformational changes, unfolding of the protein or loss of activity, cleavage of the protein
backbone [1], effects on expression and gene regulation, and affect cell signaling [2]. Studies
have shown higher levels of oxidized proteins are found with aging, oxidative stress, also with
diabetes, atherosclerosis and neurodegenerative diseases [3-6]. Amino acids liable to oxidation
[7, 8] are cysteine, methionine, tryptophan, phenylalanine, tyrosine, histidine, arginine, lysine,
proline, and threonine. Cysteine and methionine stand out as the two amino acids that are most
easily oxidized [3]. Cysteine can easily be converted to disulfide and methionine to methionine
sulfoxide.
Aerobic organisms rely on oxygen for the production of ATP during oxidative
phosphorylation. Oxygen is the ultimate electron acceptor during this biosynthesis, and water is
one of the byproducts of this reaction. However, transfer of single electron to a molecule of
oxygen results in production of superoxide anion, a highly reactive radical. The protonated
superoxide radical can react with another molecule of superoxide anion, which produces
hydrogen peroxide. Superoxide radical falls under a category of compounds called reactive
oxygen species (ROS). Physiological levels of ROS are important for cellular functions like gene
expressions, signal transduction, apoptosis and immune response [9]. However, high
concentrations of ROS can damage biomolecules like DNA, lipids and proteins. Superoxide
dismutase, an enzyme present in all aerobic organisms, along with catalase, a heme protein,
converts the superoxide radical and hydrogen peroxide into water and molecular oxygen and act
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as just one of the defense mechanisms against oxidative damage. However, oxidation of proteins
still occurs, often at methionine.
Methionine is a non polar amino acid; along with cysteine they are the only two amino
acids that contain sulfur. The sulfur atom exists as a thioether linkage in methionine. In the
presence of reactive oxygen species (ROS), methionine is converted to methionine sulfoxide. In
contrast to methionine, methionine sulfoxide’s side chain is polar. The conversion of important
methionine residues to sulfoxide within a protein, can lead alteration of structure and
functionality [10]. The sulfoxide form of methionine can be converted back to methionine by
naturally occurring methionine sulfoxide reductases (MSRs) [4, 11, 12]. It has been shown in
Alzheimer’s disease [13, 14] and aging, the physiological concentrations of MSRs are low, and
they are unable to reduce all sulfoxides. This has led to speculation that oxidative stress and
methionine oxidation contribute to the development of Alzheimer’s disease [15].
Why might oxidation of a protein lead to such far-reaching consequences as
Alzheimer’s? Proteins are ubiquitous in all biological processes, and they play crucial roles in
them. They are associated with enzyme catalysis, immune system, nerve impulses, motion,
mechanical support, transport and storage among other processes that occur within a living
organism. The remarkable range of activities proteins perform arises from their ability to fold
into unique three-dimensional structures. This allows them to interact with wide range of
molecules. Some of the noteworthy features of the native protein are: Polypeptides can fold in
such a fashion, that distant amino acid residues on the polypeptide chain can be close in
proximity to each other. Globular proteins are compact; they exclude almost all water from the
inner hydrophobic core. The native protein is stabilized in the tertiary state by the following
types of interactions. There are hydrophobic interactions, where hydrophobic side chains are
3

brought into close proximity to each other. Electrostatic interactions occur between the ionic
groups. Hydrogen bonding, where hydrogen bonds are formed between the side chains and also
between the polypeptide backbones. Covalent bonds, disulfide bonds formed between the 2
cysteine residues. If any of these interactions are disrupted, it could alter the structure of the
protein, and consequently alters the functionality of the protein, which could lead to
complications, or worse lead to development of diseases. Sickle cell anemia demonstrates how a
substitution of single amino acid can have drastic effect on the functionality of a protein. In
sickle cell anemia, body produces a variant of hemoglobin, where sixth position of the β-globin
gene codes for valine, instead of glutamic acid [16]. Could high levels of oxidation of a single
side chain in the right protein have similarly profound consequences?
Cardiovascular diseases are the number one cause of death in the United States. The
American Heart Association estimates that one out of three Americans die of cardiovascular
death, and 80,700,000 people in the United States have one or more forms of cardiovascular
disease [17, 18]. National Health and Nutrition Examination Survey (NHANES) reports 7.2% of
Americans to have some type of cardiovascular diseases. This number comprised of 3.2% with
coronary heart disease, 2.7% with stroke, and 2.0% with congestive heart failure, also many
patients reported more than 1 condition [19].
Annually 437,900 people are killed by diseases caused by smoking, and 35% of those
deaths are cardiovascular related [20]. Cigarette smoke is the major cause of pulmonary
emphysema [21], bronchitis, myocardial infarction, and stroke as well as lung cancer. Four
million people die every year from tobacco smoking related diseases worldwide. It has been
estimated that 2 billion people use tobacco products [22]. Approximately 64.5 million people in
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the USA are active smokers, between 1995-1999 the estimate of deaths that resulted from
smoking and exposure to secondhand smoke was approximately 440,000 annually [23].
Cigarette smoke and oxidation
Cells and tissues are vulnerable to oxidative damage; however due to the proximity and
function of the lung epithelial tissues, the components of the cigarette smoke makes them more
vulnerable to oxidative damage. The epithelial cells of the lungs can be damaged by cigarette
smoke from direct interaction of its components [24, 25].
Cigarette smoke is a complex mixture of over 4700 chemical compounds, including high
concentrations of reactive oxygen species (ROS) and reactive nitrogen species (RNS) [26-30].
Cigarette smoke contains epoxides, peroxides, nitric oxide (NO'), nitrogen dioxide,
peroxynitrates, semiquinone, hydroxyl radical, and many other free radicals [29]. Besides the
toxic components of cigarette smoke, lungs of cigarette smokers are further burdened by
secondary oxidative stress triggered by ROS and RNS from cigarette smoke. It has been
demonstrated that increased ROS and RNS levels leads to activation of transcription factors,
signal transduction and gene expression of proinflammatory mediators which generates
inflammation response. There are increased numbers of neutrophils and activated macrophages
in the lungs of cigarette smokers [29, 30], and they are known to release large amount of
hypochlorite, hydrogen peroxide and superoxide [31]. The inflammatory response and release of
ROS under normal conditions is important in immune response. However, when the
inflammation becomes chronic, the neutrophils and macrophages are perpetually activated, this
creates severe oxidative damage to the cells and tissues of cigarette smokers [32], and that may
predispose smokers to lung diseases.
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Emphysema and cigarette smoke
Pulmonary emphysema (PE) is disease characterized by progressive and irreversible
destruction of the lung parenchyma; it is a cause for lot of morbidity and mortality. It belongs to
class of disease clinically classified as a chronic obstructive pulmonary disorder (COPD) [3335]. In PE the air spaces distal to the terminal bronchiole are enlarged and alveolar walls are
destroyed [36], as a result the lungs loses their elastic recoil force, which is required to drive the
air out of the lungs. The volume airflow in the lungs is severely reduced due to loss of lung
elasticity. PE can be subdivided into two types. Centrilobular emphysema, which is associated
with cigarette smoke, is where there is dilation or destruction of bronchioles. Panlobular
emphysema, which results from the deficiency of α1-antitrypsin [36], is characterized by dilation
and destruction of acinus. Studies have shown that approximately 40% of heavy smokers
develop PE over the span of four decades [37].
α1-Antitrypsin is a 52-kDa glycoprotein that protects the lungs from elastic damage. It is
the major antiprotease of alveolar region; it provides protease/antiprotease balance. Neutrophil
elastase (NE), a serine protease, is capable of destroying structural components of the alveolar
wall of the lungs, α1-Antitrypsin protects the lungs from NE. In people with hereditary
deficiency of serum antitrypsin have low concentration of α1-Antitrypsin in the blood, despite
normal production by the liver. Due to low concentration of the enzyme in the blood, the
required amount of α1-Antitrypsin is unable to reach the lungs, resulting in unopposed activity of
protease, leading to systematic destruction of the lungs. People with this hereditary deficiency
usually develop PE.
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The relationship between smoking and PE has been established by many studies. In one
study, elastase inhibitory activity between smokers and non smokers were compared based on
the lung fluid obtained from the donors, the cigarette smokers had two fold reduction in their anti
elastase ability compared to the non smokers [38]. The methionine residues are oxidized to
methionine sulfoxides in α1-Antitrypsin found in broncho alveolar lavage (BAL) fluid [39]. In
order to understand the molecular basis of lowered anti elastase activity in cigarette smokers
Taggard et al. studied the effect of hydrogen peroxide, found in cigarette smoke, on the
methionine residues found in α1-Antitrypsin [40]. They found that the methionine residues were
susceptible to oxidation. There are 9 methionine residues in α1-Antitrypsin, however only 2
residues, methionine 351 and 358, are most susceptible to oxidation. Also, the oxidation of either
Met351 or Met358 resulted in inactivation of α1-Antitrypsin. They produced recombinant α1Antitrypsins, where one or both met residues were substituted with valine. The recombinant
proteins with single substitutions were not easily inactivated as the wild types, and the double
mutant was resistant to oxidative damage. They established that the oxidation of the 2
methionine residues takes away the anti elastase capacity of α1-Antitrypsin. Combination of
increased protease activity and proteases inactivation by oxidants have also been associated in
diseases like cystic fibrosis, bronchopulmonary dysplasia, hyperoxia-induced lung damage, adult
respiratory distress syndrome[40].
Hemostasis and thrombomodulin
The physiological process that stops bleeding, by formation of hemostatic plug, at the site
of an injury while maintaining normal blood flow elsewhere in the circulation is referred as
hemostasis [41]. The hemostasis can be divided into primary, secondary hemostasis and
fibrinolysis [42]. Primary hemostasis is the primary response of the platelets towards an
7

endothelial injury. In primary hemostasis, plugging of the injury results when platelets are
activated and they bind to the site of injury and with each other. Platelets circulate in the blood
for approximately 10 days and their concentration ranges from 100 to 400 million per milliliter
of blood [43]. Under normal physiological conditions they do not aggregate with each other nor
do they adhere to the surfaces. In the event of injury, several platelet receptors in presence of
their corresponding ligands activate the platelets, which results in platelets aggregation and
adherence to the injured site.
Secondary hemostasis consists of the generation of thrombin and insoluble fibrin, and
subsequent deposition of fibrin into and around the platelets on the site of injury. The fibrin
forms a crosslinked mesh that strengthens and stabilizes the clot [41]. The initiation of
secondary hemostasis involves coagulation cascade of serine proteases that results in cleavage of
soluble fibrinogen by thrombin. The presence of anticoagulants like thrombomodulin and
heparan sulfate proteoglycans prevents the activation of serine proteins cascade in normal blood
vessels. In the event of injury to the blood vessels, the blood gets exposed to tissue factor, which
activates factor VIIa [44], which subsequently activates factor X. The factor X can also be
activated by factor IXa in presence of factor VIIIa. Prothrombin is activated by factor Xa in the
presence of cofactor factor Va resulting in generation of thrombin [45]. Thrombin cleaves
fibrinogen to produce insoluble fibrin. The coagulation cascade or waterfall model of proteolytic
reactions was proposed in 1960s, and they are based on two complementary blood clotting
models [46, 47]. This cascade has received general acceptance. The steps in the coagulation
cascade look like Y-shape, with intrinsic and extrinsic pathway converging to form a common
pathway at factor Xa. The coagulation cascade has been shown to be insufficient to predict
bleeding tendency in vivo [48, 49]. In the past decade a cell based model of coagulation has been
8

proposed for the secondary hemostasis [48, 49]. This model consists of three phases: initiation,
amplification, and propagation. During initiation there is production of prothrombinase on the
cell surface the cells that express tissue factor, followed by production of low amounts of
thrombin. During the amplification step thrombin activates the platelets and cofactors V and VII.
In the propagation step, other platelets in the bloodstream are recruited on the site of injury,
which leads to generation of large amounts of thrombin, which amounts production of fibrin to
stabilize the platelet.
The third facet of hemostasis is fibrinolysis. The coagulant tendency of the primary and
the secondary hemostasis is counteracted by fibrinolysis. Plasminogen circulating in the blood is
cleaved to produce plasmin by endothelial bound tissue-type plasminogen activator. Plasmin
subsequently degrades fibrin and destroys the fibrin-platelet plug [50, 51].
Blood coagulation is a delicate balance between anti thrombotic and pro thrombotic
components, so the fibrin deposition and removal is tightly regulated, and defects in any of these
components can either lead to thrombosis or excessive bleeding. Central to hemostasis is
thrombin, a serine protease, which has created significant research interest, owing its ubiquity in
hemostasis. As previously discussed, the end product of coagulation cascade is production of
active thrombin, which catalyses the formation of fibrin from fibrinogen. Thrombin regulates the
coagulation cascade through feedbacks. Besides its role in secondary hemostasis, thrombin also
plays a vital role in primary hemostasis as an activator of platelets. Also, thrombin has long
reaching effects on inflammation, cell survival, and cell proliferation [52]. It is very important to
regulate the production of thrombin to maintain homeostasis.
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Thrombomodulin, as the name indicates, modulates the activity of thrombin. Thrombin
when bound to thrombomodulin activates protein C. Activated protein C proteolytically destroys
coagulation factors Va and VIIIa and suppresses further thrombin formation. The binding of
thrombin to thrombomodulin also activates the carboxypeptidase thrombin-activatable
fibrinolysis inhibitor (TAFI) [53]. The activation of protein C and TAFI inhibits coagulation and
fibrinolysis, making thrombomodulin key protein for the regulation of coagulation and
fibrinolysis. Thrombomodulin is a protein cofactor that is found on the endothelial cell surfaces,
at an approximate density of 50,000-100,000 molecules per cell [54], and it modulates the
activity of thrombin [55, 56]. It was discovered by Esmon and Owen in the 1960’s. The path to
their discovery started with the evidence of circulating thrombin activated protein, activated
protein C, and its precursor. Those findings led them to realize the necessity of a cofactor that
activates thrombin mediated activation of protein C. In rats, it is found predominantly in the
lungs when compared with kidney and liver [57]. Thrombomodulin, purified from human lung
endothelial membrane preparations, had an apparent MW of 78,000 Da [55]. Encoded by an
intronless gene, the mature single-chain glycoprotein in the human is 557 amino acids long.
Structurally it has 5 distinct domains. It has a short cytoplasmic tail at the C-terminus, which
anchors thrombomodulin. There are several potential sites for phosphorylation sites in the C
terminus, in spite of that this region is not well conserved across different species [58]. The
deletion of this tail in mice does not have any effect in development, survival, coagulation and
inflammation [58]. There is a well conserved membrane-spanning domain, followed by a
serine/threonine-rich domain with four potential sites for O-linked glycosylation. The
serine/threonine region supports the attachment of chondroitin sulfate, which has 20 repeating
disaccharide units and a terminal trisaccharide unit [59]. Adjacent to the serine/threonine-rich

10

region is a domain that has 6 epidermal growth factors (EGF)-like repeats, this domain is the best
characterized. This region shows disulfide bonding pattern that is seen in a typical proteinprotein interactions. The activation of protein kinase C and mitogen-activated protein kinase
(MAPK) is linked to this domain for promotion of cell division on cultured vascular smooth
muscle cells fibroblasts. The data shows that this domain is associated with atherogenesis and
proliferation, although the clinical significance has not been established [60, 61]. The first two
EGF- like repeats, which are furthest from the serine/threonine rich region, their function
remains unknown. EGF-like repeats 3, 4, 5, and 6 [62-64] have been studied in detail by several
groups and are essential for activation of Protein C by thrombin-thrombomodulin complex. The
cofactor function for thrombomodulin requires the last three of six tandemly repeated EGF-like
domains (EGF 4, 5, and 6), as well as a Ser/Thr-rich domain between EGF-like domain 6 and the
transmembrane domain. The residues 1 through 222 comprises N-terminal region of
thrombomodulin, which constitutes almost half of the extracellular portion of the protein. This
region has two potential sites for N-linked glycosylation and it also shares similarities with Ctype lectins. This lectin like domain has a compact hydrophobic core, two alpha-helices, two beta
sheets and two disulfide bonds based on computer models [65]. The lectin like domain of
thrombomodulin lacks carbohydrate recoginition domain as well as Ca2+ binding site unlike
other C-type lectins. The residues 155 through 222 of thrombomodulin might be associated with
plasma membrane and this region is hydrophobic [66]. The lectin like domain is suggested to be
globular and furthest from the plasma membrane making it in the prime position to interact with
other molecules, this results are based on electron microscopy and computer models [67]. This
region plays major role in cell adhesion, inflammation and cell proliferation but it lacks anti
coagulant function.
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Thrombin binds to thrombomodulin to activate Protein C which initiates the cascade that
stops clotting, by inactivation of clotting factors Va and VIIIa [68]. The thrombinthrombomodulin complex activates protein C 1,000-fold more when compared to activation of
protein C by thrombin alone. Deficiency in protein C or activated protein C is well established
as increasing the risk of thrombosis [69]. Low levels of thrombomodulin are a well established
risk factor for heart disease [70, 71]. Without a doubt, thrombomodulin plays a key role in
slowing or stopping clotting. It has been shown that thrombomodulin in complex with thrombin
activates thrombin activatable fibrinolysis inhibitor (TAFI) by 1250 fold [72-75]. Activated
TAFI is a plasma procarboxypeptidase B that stabilizes clot by down regulating fibrinolysis
[76]. Activated TAFI catalyzes the removal of lysine residues from the C-terminal of fibrin [77,
78], resulting in elimination of plasminogen binding site of fibrin, subsequently plasminogen is
unable to activate and prevention of fibrinolysis [79, 80] . This function of thrombomodulin
might seem contradictory to its pro-fibrinolytic function previously discussed, but this highlights
that thrombomodulin is a key regulator in coagulation, since it controls the formation and
breakdown of clots.
Thrombomodulin is anchored on the luminal surface of the endothelium and as
previously indicated, thrombomodulin lacking the cytoplasmic domain appeared normal [58].
Thrombomodulin undergoes endocytosis and degradation, and a significant amount of it is
cleaved off and it is found in blood. Thrombomodulin found in blood are heterogeneous in size,
due to differences in glycosylation [81, 82]. Four different fragments have been isolated from
blood and seven fragments ranging in size from 12 to 100kDa after reduction of disulfides [83] .
The concentration of thrombomodulin in serum and plasma are reported to be between 3 to 300
ng/mL [84]. In diseases like diabetes and lupus high levels of thrombomodulin in plasma have
12

been reported [85], this is believed to be a good marker for endothelial damage [53]. Studies
have correlated high plasma thrombomodulin levels to be associated with a low risk of
developing coronary heart disease [53].
As previously mentioned, thrombomodulin has 6 epidermal growth factor (EGF) like
domains. Generally, EGF-like domains have 40 amino acid residues, and six cysteine resides that
form three disulfide bonds [86]. Individual EGF like domains were synthesized and only the fifth
domain bound to thrombin by itself [87]. The fourth and the fifth EGF like domains consists of
81 amino acids, and the fifth domain contains most of the residues that bind to thrombin. The
EGF like domain 4 and 5 (TMEGF45) bind to thrombin more tightly than EGF 5 alone.
TMEGF45 is the smallest fragment of thrombomodulin that when bound to thrombin can
activate protein C. Addition of fourth and the fifth EGF-like domains separately, do not activate
protein C, suggesting they work together in activation of protein C [88]. The kcat values for
protein C activation by the thrombin-TMEGF45 complex, calculated by binding kinetic studies
and cofactor activity assays, shows TMEGF45 has full cofactor activity. The EGF like domain
six increases the Km value of thrombomodulin for thrombin by factor of ten, despite not altering
the Kcat value of thrombin-thrombomodulin complex for protein C [89]. The EGF 4 and 5 of
thrombomodulin is linked together by three residues, and one of them is methionine, which is the
388th residue in thrombomodulin (Met388) [90]. Figure 1.1 is thrombomodulin residues from all
mammals sequenced as of the date of writing; Met388 is conserved in all the sequences.
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LNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPNTQASCECPEG
LNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPNTRGNCECPDG
LNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPNTQASCECPEG
LNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPNTQASCECPEG
LNQTSYLCVCAEGFAPIPHQPHRCQMFCNQTACPADCDPNTQANCECPEG
LNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPNTRGNCECPDG
LNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPNTRGNCECPDG
LGQTSYRCICAEGFAPVPQQPHRCQMFCNQTACPADCDPNTKSNCECPEG
LGQTSYRCICAEGFAPVPQEPHRCQMFCNQTACPADCDPNTKSNCECPEG
LNQTSYLCVCAEGFAPIPHEPHRCQMFCNQTACPADCDPNTRGNCECPDG
VGQTDYHCICAEGFAPSPHDPHRCQMFCNQTACPADCDPNSPTSCQCPEG
LGHTGYRCVCAEGFAPNPLDPHRCQMFCNETACPADCDPNSLDSCQCPDG
LNQTSYLCVCAEGFAPVPHEPHRCQMFCNQTACPAVCDSNTQANCECPEG
VSQTDYRCICAEGFAPVPHDPHRCQMFCNQTACPADCDPNSPTSCQCPEG
VGPTNYTCICAEGFVPKPQEPSRCQMFCNQTSCPADCDPNTPADCKCPEG
VGQTDYRCICAEGFAPSPHDPQRCLMFCNQTACPADCDPYSPTSCQCPEG
VGQNDYRCICAEGFVPSPQAPHRCQMFCNQTTCPADCDPNNPDSCQCPDG
VGRTGYRCVCAEGFAPVPHAPHRCQMFCNQTSCPADCDPNKQDSCQCPDG
VGRSEHKCICAEGFAPVPGAPHKCQMFCNQTSCPADCDPHYPTICRCPEG
VSPTDYRCICAPGFAPKPDEPHKCEMFCNETSCPADCDPNSPTVCECPEG
VNSTHYNCICAEGFAPKLDDPDRCEMFCNETSCPADCDPNSPSFCQCPEG
VSPTEYICICAEGFAPKPGEPHRCEMFCNESSCPADCDPNTPDFCHCPEG
LGQ-NYRCICAEGFAPVPDEPHRCQMFCNQTTCPADCDPNYPSTCLCPEG
VGRSEHQCICAEGFAPVPGAPHKCRMFCNQTSCPADCDPHNPAVCWCPEG
VGHTNYQCVCAEGFVPNAHDPHRCQMFCNTTSCPADCDPNNPATCQCPEG
VGTDKYECICAEGFIPNPKEPYRCQMFCNQTECPADCDPNNLNICYCPEG
VGRSEHKCICAEGFAPVPGAPHKCRMFCNQTSCPADCDPHYPTICRCPEG
VGQTDYRCICAEGFAPSLQDPHRCRMFCNQTSCPADCDPNTPGSCQCPEG
LKET*YRCICAEGFAPVPHAQHKCQMFCNQTECPADCDPNYPDICRCPDG
VGQNDYRCICAEGFAPIPQDPDRCQMFCNQTACPADCDPNNPSNCQCPEG

Homo sapiens
Saimiri sciureus
Pan troglodytes
Pan paniscus
Nomascus leucogenys
Macaca mulatta
Papio Anubis
Callithrix jacchus
Saimiri boliviensis
Macaca fascicularis
Ailuropoda melanoleuca
Loxodonta africana
Pongo abelii
Canis familiaris
Otolemur garnettii
Mustela putorius furo
Felis catus
Sus scrofa
Bos taurus
Mus musculus
Rattus norvegicus
Cricetulus griseus
Oryctolagus cuniculus
Ovis aries
Pteropus alecto
Heterocephalus glaber
Bos grunniens mutus
Tupaia chinensis
Myotis davidii
Equus caballus

Human
Squirrel monkey
Chimpanzee
Bonobo
Nor. white-cheeked gibbon
Rhesus monkey
Olive Baboon
Common marmoset
Black-capped squirrel monkey
Crab-eating macaque
Giant Panda
African bush elephant
Sumatran orangutan
Dog
Greater galago
Ferret
Cat
Pig
Cow
Mouse
Rat
Chinese hamster
Rabbit
Sheep
Black flying fox
Naked mole rat
Yak
Tree shrew
David’s myotis
Horse

Figure 1.1: Alignment of region of interest of thrombomodulin amino acid sequences from
different mammals. Methionine 388 is conserved in all these organisms.

The mutation of Met388 to any other residues, except leucine, decreases the
anticoagulant cofactor activity of thrombomodulin [91]. More importantly, there is 76-90% loss
of activity when Met388 is oxidized using H2O2 [92]. There are four other methionines in
thrombomodulin, but their oxidation does not disrupt the ability to activate protein C [92]. The
Kd of thrombomodulin thrombin interaction increases to 10.9 from 4.4nM, when a full length
thrombomodulin had oxidized Met388 [93]. TMEGF45 with oxidized Met388 has 3.5 fold lower
Kcat, and 3.3 fold higher Km values when compared to wild type TMEGF45 based on protein C
activation assays [94]. It must also be mentioned that clot stabilizing activation of TAFI by
thrombin-thrombomodulin complex is unaffected by the oxidation of Met388 [95]. Since the
activation of clot stabilizing activated TAFI, a procoagulant pathway, is unaffected by Met388
oxidation, while activation of protein C, an anticoagulant pathway, is suppressed by oxidation of
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Met388. Although effects oxidation of Met388 on activation of protein C and TAFI were
demonstrated in vitro, it seems that oxidation of Met388 leads hemostasis towards pro
coagulation, and higher rates of formation of clots when significant amounts of Met388 is
oxidized.

Figure 1.2: Schematic diagram of TMEGF45. It consists of 81 amino acids. The fifth domain
contains most of the residues that bind to thrombin. TMEGF45 is the smallest fragment of
thrombomodulin that when bound to thrombin can activate protein C.
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Figure 1.3: Structure of Methionine and Methionine Sulfoxide

The structures TMEGF45 and TMEGF456-thrombin complex have been investigated
using NMR to understand the interactions of Met388 [94] in thrombomodulin. Met388 plays at
least two structural roles. First, Met388 is important part of the fifth domain’s hydrophobic
region, and there is disruption of the hydrophobic interactions when the methionine is oxidized
to methionine sulfoxide. Second, the interaction between the fourth and the fifth domain of
thrombomodulin is mediated by methionine, and conversion to methionine sulfoxide has
potential to disrupt the orientation of the two domains. There is a significant structural difference
between oxidized and non oxidized forms in the fifth domain of thrombomodulin. Phenylalanine
376, located in the fourth domain, packs against the hydrophobic methionine but occupies a
substantially different position when the hydrophilic sulfoxide form is present, making it a key
part of the conformational switch. These structural changes bury several residues which interact
with thrombin in the structure of the thrombomodulin-thrombin complex [96].
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Is a decrease in thrombomodulin activity biologically relevant?
As mentioned previously, in vitro studies have shown that oxidation of Met388 leads to
decrease of thrombomodulin anticoagulant cofactor activity. But is this decrease in activity
biologically relevant? Could there be sufficient thrombomodulin in reserve, so that oxidation to
some of the thrombomodulin is inconsequential? In a study conducted in mices, the intronless
thrombomodulin gene was deleted to create a model for thrombotic disease [97]. The study
found complete absence of thrombomodulin resulted in death of embryos at day 9.5, the death
preceded before the functional cardiovascular system was assembled. In another study in mice,
glutamate at position 387, which is the part of the linker region connecting EGF like domain four
and five of thrombomodulin, was replaced with proline [98]. The Met388 is adjacent to
glutamate 387, which make this study relevant to our hypothesis. This study found there was a
decrease in the ability of mutant protein to activate protein C. The kcat was 37% of wild-type, Kd
for thrombin was down by a factor of 45, and Km for protein C was increased by 1.6 fold. The
amount of thrombomodulin purified, decreased by factor of three, possibly due to decreased
amount of proteins expression on the cell surface or due to turnover increase. The cell culture
experiments showed that mutant endothelial cells ability to activate protein C was reduced by 38
fold when compared to wild type cells. Despite the significant decrease in the activation of
protein C in the recombinant animals, they were viable and reproduced normally. However, these
animals showed cardiovascular diseases reminiscent symptoms, they had fibrin deposition and
small blood clots in lungs, spleen and the heart [99]. The fibrin deposition was tenfold more in
the recombinant mice when compared with normal mice at three to 6 months of age [100].
Myocardial infarction is a common and potentially fatal consequence of thrombosis resulting
from imbalance of fibrin deposition and removal [101]. In the follow up to the recombinant
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thrombomodulin study, it was shown that the recombinant mice were in hypercoagulable state
with a tendency towards sepsis and thrombosis. Such conclusion was inferred from accelerated
rate of platelet dependent thrombus formation after FeCl3 induced endothelial injury was
subjected to the carotid artery [102]. 80% of recombinant mice showed full thrombotic occlusion
when subjected to FeCl3 treatment, alternatively only 27% of the wild type mice showed such
symptoms [102]. The carotid arteries of recombinant and wild-type mice were permanently
blocked near carotid bifurcation by ligation. These animals recovered from surgery without any
complications. The recombinant mice showed severe thrombotic occlusion which spanned over
the entire length of the artery, whereas wild type mice showed thrombotic occlusion within 1mm
from the ligation site [102]. When injected with lipopolysaccharide to induce infection, in
recombinant mice resulted in much higher fatality compared to the wild-type, also in the mutant
mice fatality occurred much earlier when injected with lipopolysaccharide [102].
Prolylcarboxypeptidase (PRCP) is an endothelial membrane-bound serine
carboxypeptidase responsible for activation of bradykinin and angiotensin [103-105]. Both
proteins regulate the vascular NO to provide protection from thrombosis. PRCP is indirectly
involved in maintenance of normal blood pressure and reduction of thrombosis risk. PRCP
polymorphism has been associated with hypertension and inflammation [106]. PRCP genetrapped mice are hypertensive and are prone to faster thrombosis [107]. These mice have
increased in vivo vascular ROS and uncoupled endothelial nitric oxide synthase (eNOS) and
reduced expression of vascular thrombomodulin in their aorta [108-110]. The hypertensive and
prothrombotic state in PRCP gene trapped mice was abrogated by antioxidant treatment. This
shows the hypertensive and prothrombotic state arose from high levels of ROS in PRCP gene
trapped mice. More importantly, the knockdown of PRCP by silencing RNA (siRNA) in Human
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umbilical vein endothelial cells (HUVECs) resulted in increased uncoupled eNOS and 90%
reduction in Protein C activation. The data obtained from thrombomodulin antigen showed no
significant change (p= 0.30) in expression of thrombomodulin in siRNA knockdowns of PRCP
HUVECs [107]. The thrombomodulin was expressed but it was unable to activate Protein C. The
paper speculates that the inactivation of Protein C could caused by ROS inactivation of critical
methionine for functionality of thrombomodulin. This paper demonstrates that oxidation caused
by high level of ROS prevents thrombomodulin from activation of Protein C in a semi in vivo
environment (HUVECs).
The most common cardiovascular diseases seen in smokers are myocardial infarction and
stroke. The blood of smoker is more prone to clot than non smoker; they are in hypercoagulable
state. The narrowing of the arteries resulting from atherosclerosis increases the possibility of
cardiovascular diseases [111], equally important is the hypercoagulable state seen in smokers.
The fact that smokers have a hypercoagulable state has been established; however, despite
intensive research the molecular origin of such a state has not been shown. Free radical mediated
oxidative damage to the endothelium is considered to be an important factor for the development
of cardiovascular diseases in smokers. Most of the research in this area has been focused on
nitric oxide signaling impairment caused by oxidation [112-114]. As in emphysema, where
oxidation of key methionine residues is the molecular basis of the disease, it is our belief that
similar oxidation is taking place in the methionine 388 of thrombomodulin in cigarette smokers
from the oxidation that occurs from smoking. We strongly believe that oxidation of methionine
388 in thrombomodulin is an important molecular factor leading to cardiovascular diseases in
smokers.
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As was mentioned earlier in this chapter, thrombomodulin is predominantly located in the
lungs [115, 116] making it more vulnerable to oxidants found in cigarette smoke. The oxidants
secreted by immune cells in the lungs in response to cigarette smoke, makes lung endothelium
very oxidizing. It must be pointed out that oxidation of methionine in smokers and non smokers
have not been measured so far, however the plasma levels of thrombomodulin in smokers and
non smokers have been examined.
It has been shown that high levels of cigarette smoke exposure causes decrease in
activated protein C, and there was direct correlation between the levels of protein C with the
degree of cigarette smoke exposure [117]. This study found that activated protein C circulating
in the blood were 23.3% lower in smokers than in non smokers. There could be several factors
that contribute towards the low level of activated protein C in smokers, but based on the
evidences we have seen so far; it seems very likely that methionine oxidation of thrombomodulin
causes lower activation of protein C in smokers. Venous thromboembolism has been strongly
linked to low levels of activated protein C [118, 119], also low levels of activated protein C are
considered to be a risk factor for ischemic stroke [120]. The comparison of protein C levels in
smokers and non smokers, and relation between thromboembolism and ischemic stroke study
strengthens our case for a link between thrombomodulin oxidation and cigarette smoke as an
important molecular cause of cardiovascular diseases.
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CHAPTER 2: METHODS EXPLORED FOR QUANTIFICATION OF METHIONINE 388
OXIDATION IN HUMAN URINARY THROMBOMODULIN
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Introduction
In the first chapter we hypothesized that the methionine 388 of thrombomodulin is more
oxidized in cigarette smokers than in non smokers. We speculated that this could be the key
molecular mechanism behind the prothrombotic state seen in smokers, hence, an important
contributor towards the development of cardiovascular disease in smokers. In order to quantify
the oxidation of methionine in thrombomodulin isolated from urine, a rapid method of isolation
of the protein is necessary to process a reasonable number of samples and minimize any
oxidation during processing. In this chapter we will discuss the method we have developed to
quantitate the methionine 388 oxidation in thrombomodulin, as well as the other methods that
were attempted.
Thrombomodulin is critically important for hemostasis [121-124]. As the name implies
thrombomodulin serves to regulate the activity of thrombin. The thrombomodulin-thrombin
complex activates protein C, and the activation results in degradation of the factors that promote
clotting cascade [125]. The activated protein C or deficiency in protein C has been linked to
increased risk of thrombosis [126-128]. Low levels of thrombomodulin have been established as
a risk factor for heart diseases [71, 129, 130]. Thrombomodulin is also involved in activation of
activatable fibrinolysis inhibitor (TAFI). Thrombin when complexed with thrombomodulin
activates TAFI, activated TAFI stabilizes clot [76]. It is worth reflecting on this point that
thrombomodulin controls the rate of formation of clot as well as its breakdown.
Thrombomodulin is anchored on the luminal surface of the endothelium [131, 132]. It is
found in at much higher levels at the lungs of rats compared in kidney or liver [115, 133, 134].
The trans membrane helix and the C-terminal cytoplasmic domain of thrombomodulin anchors
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the protein and they have not been demonstrated to have direct functional role to hemostasis.
Mice lacking the cytoplasmic domain appeared normal besides the elevated levels of
thrombomodulin in the plasma [58, 135]. Significant amounts of thrombomodulin is cleaved off
from the surface and it circulates in the blood [136, 137]. The thrombomodulin circulating in the
blood is not homogenous in size partly due to the differences in glycosylation [138, 139] and
mostly due to variation in proteolysis of thrombomodulin. Four different protein fragments have
been isolated from plasma, and following reduction of disulfides, seven fragments that range
from 12 to 100 kDa in size have been isolated [121, 140, 141]. These fragments are able to
activate protein C when complexed with thrombin, however their activity drops to 16-50% when
compared to the membrane bound intact thrombomodulin [142]. The literature values for
thrombomodulin in serum and plasma has been reported to be between 3 to 300 ng/ml [84, 121,
143, 144]. High concentrations of thrombomodulin are a good indicator of endothelial damage
and have been reported in many diseases and conditions like lupus, preeclampsia, and diabetes
[145].
In vitro oxidation of methionine 388 of thrombomodulin has been shown to lower the
ability of thrombin-thrombomodulin complex to active protein C [146]. When the methionine
388 was substituted with leucine, the mutant was insensitive to oxidation and it activated protein
C [147, 148]. The oxidation of methionine 388 in thrombomodulin has been shown to have no
effect on TAFI activation by thrombomodulin-thrombin complex [149]. Since oxidation of
methionine 388 promotes clotting by lowered activation of protein C and has no effect in the clot
stabilizing by TAFI, methionine 388 oxidation of thrombomodulin in humans should be a factor
promoting hypercoagulable state.
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There is good reason to try to determine how much oxidation of this amino acid side
chain actually occurs in vivo. The quantification of urinary thrombomodulin methionine 388
oxidation involves 3 three major steps: 1) purification of thrombomodulin from urine, 2)
digestion of purified thrombomodulin 3) quantification of methionine oxidation. In this chapter
we report several methods that were tested to arrive at a protocol to successfully perform the
aforementioned three major steps.
Materials and Methods:
Purification of thrombomodulin
Detection of thrombomodulin by ELISA
The concentration of thrombomodulin in various fractions throughout the course of
purification was followed using a commercially available sandwich enzyme linked
immunoabsorbant assay (ELISA) kit for thrombomodulin (American Diagnostica, Greenwich,
CT).
Urine sample collection
The University of Arkansas Institutional Review Board approved all experimental
protocols using human subjects. Samples of the first morning urinate were collected by
volunteers in 400 mL centrifuge bottles. Thiodiglycol (5 mL) and 0.5 M EDTA (1 mL, pH 8.0)
were added to containers before sample collection. The collected samples were transported
using an insulated bag containing an ice pack. The samples were generally transported to the
laboratory within two hours of collection and stored at 4 °C for no longer than 2 hours before
further processing to minimize the opportunity for oxidation. Typical volumes of the sample
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from a donor ranged from 200-550 mL. Prior to processing, 1 mL of sample was removed and
stored in -80°C for determination of the initial thrombomodulin concentration in the sample.
Jumbosep spin filter
Jumbosep spin filters were tested for the concentration of the urine sample. The
Jumbosep centrifugal device (Pall) consists of sample reservoir, membrane filter insert, and the
filtrate receiver. The sample reservoir has a maximum capacity of 60 mL. The membrane filters
are constructed from modified polyethersulfone on polyethylene substrate, and they are low
protein binding. A membrane filter with molecular weight cut off of 30 kd was used for
purification. 60 mL of urine sample that was previously cooled at 4 °C, and centrifuged in
Sorvall GS-3 rotor at 4,000 rpm for 30 min at 4 °C was added to the sample reservoir. The
Jumbosep filter was centrifuged at 3500 rpm in a SH-3000 rotor for 30 minutes at 4 °C. After
centrifugation for 30 minutes, the filtrate was removed and more urine sample was added to the
sample reservoir and centrifuged. The previous step was repeated until entire urine sample was
passed through the filter, and the final volume in the reservoir was 20 mL. Next, buffer exchange
was performed to adjust pH and the ionic strength of the urine concentrate. 40 mL of 25 mM
imidazole acetate at pH 5.5 was added to the sample reservoir, and the Jumbosep filter was
centrifuged for 30 minutes. The buffer exchange was repeated two more times. The buffer
exchanged concentrated urine sample was collected for downstream processing. Slurry of SP
Sepharose FF was poured into a 12 mL Econo-Pac gravity-flow polypropylene column in a
sufficient amount to pack a 1 ml bed volume. The column was equilibrated using 10 mL of 25
mM imidazole acetate, pH 5.5. Urinary protein concentrate following Jumbosep was passed
through the column, and the column was washed with 3 mL of 25 mM imidazole acetate, pH 5.5.
The flow through and the wash from the SP Sepharose column was collected in 50 mL conical
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flask. Slurry of Q Sepharose FF was poured into a 12 mL Econo-Pac gravity-flow polypropylene
column in a sufficient amount to pack 2 ml bed volume. This column was equilibrated using 10
mL of 25 mM imidazole acetate, pH 5.5. The pooled flow through and wash from the SP
Sepharose was passed through the Q Sepharose column. The column was washed with 8 mL of
25 mM imidazole acetate, pH 5.5. Thrombomodulin was eluted by passing 8 mL of 0.5 M NaCl,
20 mM imidazole acetate, pH 5.5 through the column, elutes were collected in one mL fractions.
The crude thrombomodulin typically eluted in the fourth through sixth fractions. The fractions
containing thrombomodulin, tested using ELISA, were flash frozen in liquid nitrogen and
lyophilized. The dried samples were stored at -20 °C or immediately subjected to HPLC
purification.
Tangential flow filtration (TFF) system
Labscale Tangential Flow Filtration (TFF) System, manufactured by Millipore, was
tested for the concentration of the urine sample. The Labscale TFF System has a graduated
500 mL acrylic reservoir with a retentate backpressure valve, feed and retentate pressure
indicators, and a stirrer assembly. A Pelicon XL filter with 30 kd MW cutoff Biomax membrane
was attached to the TFF system. The urine sample cooled at 4 °C, and centrifuged in Sorvall GS3 rotor at 4,000 rpm for 30 min at 4 °C was poured into the TFF reservoir. The sample was
concentrated until the urine sample was concentrated to the final volume of approximately 25
mL. 400 ml of 25 mM imidazole acetate buffer pH 5.5 was added to the concentrate, and this
solution was concentrated to 20 mL to exchange the salts from the urine. The buffer exchange
was repeated until the sample was clear. Slurry of SP Sepharose FF was poured into a 12 mL
Econo-Pac gravity-flow polypropylene column in a sufficient amount to pack a 1 ml bed volume.
The column was equilibrated using 10 mL of 25 mM imidazole acetate, pH 5.5. Urinary protein
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concentrate following Jumbosep was passed through the column, and the column was washed
with 3 mL of 25 mM imidazole acetate, pH 5.5. The flow through and the wash from the SP
Sepharose column was collected in 50 mL conical flask. Slurry of Q Sepharose FF was poured
into a 12 mL Econo-Pac gravity-flow polypropylene column in a sufficient amount to pack 2 ml
bed volume. This column was equilibrated using 10 mL of 25 mM imidazole acetate, pH 5.5.
The pooled flow through and wash from the SP Sepharose was passed through the Q Sepharose
column. The column was washed with 8 mL of 25 mM imidazole acetate, pH 5.5.
Thrombomodulin was eluted by passing 8 mL of 0.5 M NaCl, 20 mM imidazole acetate, pH 5.5
through the column, elutes were collected in one mL fractions. The crude thrombomodulin
typically eluted in the fourth through sixth fractions. The fractions containing thrombomodulin,
tested using ELISA, were flash frozen in liquid nitrogen and lyophilized. The dried samples were
stored at -20 °C or immediately subjected to HPLC purification.
Ion exchange chromatography
The urine sample that was previously cooled at 4 °C was centrifuged in a Sorvall GS-3
rotor at 4,000 rpm for 30 min at 4°C. The supernate was then filtered using a bottle-top 0.22 µm
polyethersulfone (PES) membrane filter to remove remaining particulates and cellular debris.
Sufficient 0.25 M imidazole buffer, pH 6.0 was added to the urine filtrate to bring to a final
concentration of 25 mM imidazole acetate. Next, the pH of the sample was adjusted to 6.0 by
addition of 2 M acetic acid or 6 M NaOH depending on the urine sample. Typically after the
addition of 0.25 M imidazole buffer, the pH of the samples ranged from pH 5.5-6.4. The pH of
the sample was measured using a pH electrode. A slurry of Q Sepharose FF (GE Healthcare) was
poured into a 50 mL Bio-Rad Econo column in sufficient amount to pack a 20 ml bed volume. A
Fluid Metering, Inc (FMI) pump was connected to the Bio-Rad column to pump buffer and urine
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sample through the Q Sepharose column at a constant speed of 5 mL/min. The column was first
equilibrated with 60 mL of 25 mM imidazole acetate, pH 6.0. Next, the urine sample was passed
through the column. The column was washed with 50 mL of 25mM imidazole acetate, pH 6.0
and then by addition of 20 mL of 25 mM imidazole acetate buffer, pH 6.0, 50 mM NaCl.
Fractions containing thrombomodulin were eluted by addition of 50 mL of 25 mM imidazole
acetate buffer, pH 6.0, 0.5 M NaCl. The 0.5 M NaCl fractions were collected in 15 mL conical
tubes, 5 mL in each tube. The eluent after addition of 25 mL of 25 mM imidazole acetate buffer,
pH 6.0, 0.5 M NaCl, tested positive for thrombomodulin. A solution of 0.2 M L-methionine
(Sigma-Aldrich) was added to thrombomodulin containing fractions to a final concentration of 2
mM methionine. The fractions were transferred to 1.5 mL microcentrifuge tubes, typically 14
tubes, and flash frozen in liquid nitrogen. The frozen eluents in 1.5 mL microcentrifuge tubes
were dried under vacuum in a SpeedVac concentrator system using medium heat (45°C).
Multiple urine samples were collected from each donor since there was usually not
enough thrombomodulin isolated from a single sample to reliably observe it by mass
spectrometry. Typically, three different urine samples were collected from each donor. These
three samples were usually collected from each donor on consecutive days. Each sample was
purified by ion exchange the very day it was collected. The thrombomodulin containing fractions
were flash frozen, and were stored in -20 °C. The thrombomodulin containing HPLC fractions
from different samples were pooled before chymotrypsin digestion.
Reverse phase HPLC purification.
The dried samples from Jumbosep filtration, TFF, or ion exchange were dissolved in
minimum volume, generally 5 mL of total volume, of 18.2 megohm deionized water. The
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dissolved sample was passed through a 25 mm syringe filter with 0.2 µM PES membrane
(VWR). The 4 sets of 1.375 mL redissolved sample were injected into reverse phase Waters
HPLC system. An Atlantis dC18, 5 μm particle, 4.6x250 mm column held at 58 °C and a 2996
photodiode array detector monitoring 214 nm and 254 nm was used. Upon injection, a gradient
was run at 1 mL/min from 10 to 29% acetonitrile, 0.1% trifluroacetic acid over 12 minutes, and
then from 29% to 40% acetonitrile over the next 11 minutes, and then from 40% to 90%
acetonitrile over the next 25 minutes. The eluents were collected in 1 mL fractions in 1.5 mL
eppendorf tubes, to which were previously added 100 uL of 200 mM Tris buffer, pH 8.0. The
thrombomodulin containing fragments, identified by ELISA, eluted at 30 minute. The HPLC
method for purification of thrombomodulin was developed by Dr. Jeffery Froude, former
graduate student in Stites Lab. His method was used as a template to develop the current method.
The two methods differ in their gradient profile, the new method provides a better resolution of
the thrombomodulin containing peak. The thrombomodulin containing 1.5 mL microfuge tubes
were flash frozen in liquid nitrogen, dried under vacuum in a SpeedVac concentrator system
using medium heat. The HPLC Atlantis column was cleaned using 1.0 mL/min of 90%
MeCN/0.1% TFA for 10 minutes, followed by equilibration to the starting conditions of 1.0
mL/min of 10% MeCN/0.1% TFA in preparation for the next injection.

Digestion of thrombomodulin
Digestion using manufacturer’s protocol
The thrombomodulin containing fractions from the reverse phase chromatography was
pooled and dissolved in approximately 100 uL of 1X phosphate buffered saline (PBS; 1.46 mM
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KH2PO4, 9.9 mM Na2HPO4, 2.68 mM KCl, 137 mM NaCl, pH 7.4). If the solution did not turn
clear after the addition of the buffer, the sample was spun in a microcentrifuge (Galaxy 14D
VWR) at 13K RPM for a minute. The supernatants were removed, and precipitates were
dissolved in 75 µL of 1X phosphate buffered saline. Freshly prepared triscarboxyethylphosphine (TCEP) was added to make the final concentration of 50 mM TCEP. 10
µL of 0.5 M sodium phosphate buffer pH 7.5 added to the sample, prior to addition of 500 units
of PNGase F (New England Biolabs). The samples were incubated with gentle shaking at 37 °C
for 2 hours to deglycosylate the sample. The protein was then digested at 30 °C for 8 hours after
adding 4.1 μg of sequencing grade chymotrypsin (Princeton Separations) dissolved in 50 mM
Tris-HCl, 1 mM CaCl2, pH 8.0. The chymotrypsin was inactivated by placing the samples in a
100 °C dry bath for 30 seconds. The samples were immediately flash frozen, and stored in -20 °C
until further processing.
Digestion using urea
The dried thrombomodulin containing HPLC fractions were redissolved in freshly
prepared 150 µL 45 mM sodium phosphate buffer, 2.5 M urea pH 7.75. Freshly prepared 1 M
TCEP was added to the final concentration of 10 mM. The sample was incubated in room
temperature for 10 min. The sample was placed in a 65 °C heat block for 10 min, then
immediately cooled on ice. 50 units of PNGase F (2 µL) was added to the sample and incubated
at 37 °C for 4 hours. 5 µg of sequencing grade chymotrypsin was dissolved in 5 µL of 50 mM
Tris-HCl pH 8.0, 1 mM CaCl2. The dissolved chymotrypsin was added to the sample and
incubated in room temperature for 4, 12, or 36 hours.
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Alternatively, thrombomodulin digestion was conducted using minimal volume of 45
mM sodium phosphate buffer, 8 M urea pH 7.75. The volume of buffer used ranged from 100 –
150 µL. Freshly prepared TCEP was added to the final concentration of 10 mM. The sample
was placed on 100 °C heat block for 20 min, then immediately cooled on ice. The concentration
of urea was decreased from 8 M to 4 M by addition of 45 mM sodium phosphate buffer, pH 7.75.
50 units of PNGase F was added to the sample and incubated at 37°C for 4 hours. 10 µg of
sequencing grade chymotrypsin was added to the sample and incubated in room temperature for
24 hours.
Digestion using acetonitrile
The dried thrombomodulin containing HPLC fractions were resuspended in 100 µL of
80% acetonitrile/20% 50 mM Tris-HCl/10 mM CaCl2 pH 8.0 buffer solution. Freshly prepared
0.1 M TCEP was added to the final concentration of 10 mM. The sample was incubated in room
temperature for 10 minutes. 50 units of PNGaseF was added and incubated at 37 °C for 1 hour. 5
µL of fresh sequencing grade chymotrypsin (1µg/µL) was added and incubated for 4- 24 hours.
This experiment was repeated with acetonitrile concentration at 20, 40, and 50%.
Digestion using Invitrosol
The Invitrosol LC/MS Protein Solubilizer (Invitrogen Corporation) was purchased to
assist in thrombomodulin digestion. This proprietary surfactant blend claimed to solubilize
hydrophobic proteins, not interfere with protease activity, and be compatible with reverse-phase
high pressure liquid chromatography separations of digested peptides. The dried
thrombomodulin containing HPLC fragments were reconstituted in 90 µL of 25 mM ammonium
bicarbonate, pH 8.0. 10 µL of 5X Invitrosol was added, and sonicated for 10 min. The solution
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was heated for 15 min at 60°C, and then cooled to room temperature by placing it on ice. Freshly
prepared 0.1 M TCEP was added to the final concentration of 10 mM. The solution was
incubated for 20 min at room temperature. 50 units of PNGaseF was added and incubated at 37
°C for 4 hour. 5 µL of fresh sequencing grade chymotrypsin (1µg/µL) was added and the sample
was incubated for 12 hours at room temperature. The supernatant was removed and injected into
the waters HPLC.
Digestion using RapiGest
RapiGest SF (Waters Corporation) is a reagent used to enhance the in-solution digestion
of proteins. It enhances the digestion of proteins by making the proteins more soluble in solution.
0.1 % (w/v) solution of RapiGest SF was prepared by dissolving 1 mg of lyophilized RapiGest
SF in 1 mL of 50 mM ammonium bicarbonate buffer, pH 8.0. The dried thrombomodulin
containing HPLC fragments were dissolved in 50 µL of 0.1 % RapiGest SF solution. Freshly
prepared 0.1 M TCEP was added to the final concentration of 10 mM. The solution was heated
for 10 min at 100°C, and then cooled to room temperature by placing it on ice. 50 units of
PNGaseF was added and incubated at 37 °C for 4 hour. 5 µL of fresh sequencing grade
chymotrypsin (1µg/µL) was added and the sample was incubated for 12 hours. TFA was added
to the final concentration of 0.5%, and incubated at 37°C for 30 minutes to cleave the RapiGest
SF. The sample was centrifuged at 13, 000 rpm for 10 minutes. The supernatant was removed
and injected into the HPLC.
Digestion using RapiGest and EDTA
The dried thrombomodulin containing HPLC fractions were dissolved in 100 µL of 0.2%
RapiGest in 50mM Bis-Tris, 4 mM EDTA, pH 6.0 buffer. The sample was sonicated for 1 hour.
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Sufficient 0.35 M TCEP was added to make the final TCEP concentration of 20 mM. The sample
was incubated at 60 °C for 30 minutes. 100 units of PNGaseF was added and incubated at 37 °C
for 4 hours. 5 µL of fresh sequencing grade chymotrypsin (1µg/µL) was added and the sample
was incubated for 12 hours at room temperature. The supernatant was removed and injected into
the HPLC. The reaction was quenched and RapiGest decomposed with addition of TFA to final
concentration of 25% TFA. The sample was injected into the HPLC.

Quantification of methionine oxidation
Alkylation of cysteine by fluorescent reagent
The alkylation of cysteine by fluorescent reagent to thrombomodulin isolated from urine
was performed for identification and quantification of our peptide. The three potential
advantages of alkylation are increased sensitivity, fewer peaks detected by the fluorescent
detector and, finally, alkylation prevents disulfide bond reformation. Synthetic peptide,
APIPHEPHRCQMF, was alkylated with 5-((((2-iodoacetyl)amino)ethyl)amino)naphthalene-1sulfonic acid (1,5-IAEDANS)[150, 151]. 1, 5-IAEDANS has excitation wavelength of 336 nm
and an emission wavelength of 490 nm.
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`
Figure 2.1: Chemical structure of 1, 5-IAEDANS, molar mass is 434.25 g, excitation wavelength
is 340 nm, and emission wavelength is 460 nm [152, 153].

The 2 uL of 10 mg/mL synthetic peptide stock solution was dissolved in 198 µL 0.1 M
Tris pH 8.0 that had 50 mM tris-carboxyethylphosphine (TCEP). The sample was incubated for
10 minutes at room temperature. Next, 5 fold molar excess of 1,5-IAEDANS over total thiols
was added. The samples were incubated for 8 hrs. 10 fold molar excess of 2-mercaptoethanol (2ME) over 1,5-IAEDANS was added to the sample after alkylation [154]. The sample was
injected into the Waters ACQUITY UPLC System, BEH 130 C18 1.7 µm 2.1x150 mm column
that was heated to 45°C, 0.4 mL/min flow rate. The PDA detector monitored at 214nm and
fluorescence (FLR) detector excitation wavelength was 340 nm, and emission was monitored at
460 nm). The initial solvent composition 10% MeCN/0.1% TFA, and it was transitioned to 20%
MeCN/0.1% TFA in a convex curve gradient over two minutes. Over the next 2.5 minutes, a
linear gradient from 20% MeCN/0.1% TFA to 42% MeCN/0.1% TFA was run.
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Determination of methionine 388 oxidation ratio by UPLC
Following chymotrypsin digestion, the thrombomodulin fragments were injected into a
Waters Acquity UPLC System with the detector monitoring 214 nm. The BEH 130 C18 1.7 µm
2.1x150 mm reverse phase column was heated to 45 °C and a 0.2 mL/min flow rate was used to
separate the peptide mixture. The eluent was started at 10% MeCN/0.1% TFA and transitioned to
20% MeCN/0.1% TFA over two minutes. Over the next 2.5 minutes, a linear gradient from 20%
MeCN/0.1% TFA to 42% MeCN/0.1% TFA was run. The methionine and methionine sulfoxide
forms of the peptide APIPHEPHRCQMF eluted at 11.5 and 22.2 minutes, respectively. The
peptide APIPHEPHRCQMF (synthesized by SIGMA Genosys) in the methionine and/or
methionine sulfoxide forms was co-injected to confirm peak position. After the run, the column
was cleaned with 0.20 mL/min of 90% MeCN/0.1% TFA for 8 minutes followed by 5 minutes
equilibration to 0.2 mL/min of 10% MeCN/0.1% TFA.
Mass spectrometry analysis of methionine 388 oxidation
The presence of oxidized and reduced forms of peptide in the chymotrypsin digested
thrombomodulin was confirmed by matrix-assisted laser desorption/ionization (MALDI) mass
spectrometry. The MALDI analysis was performed by the Statewide Mass Spectrometry Facility
located at the University of Arkansas. The pure samples were mixed with the MALDI matrix, 2,
5-dihydroxybenzoic acid (DHB) (Sigma Aldrich). MALDI-TOF mass spectra were obtained on
a Bruker Ultraflex II (Bruker Daltonic GMBH, Bremen, Germany) time-of-flight mass
spectrometer operated in the positive-ion reflectron mode. The accelerating voltage, delayed
extraction time, and laser power were adjusted to optimize sensitivity and resolution for ions
between m/z 500 – 4000.
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Recombinant TMEGF 456
To conduct a study of the oxidation of methionine in the thrombomodulin of smokers and
non-smokers we were successful in purifying thrombomodulin from urine, however the
quantities were not sufficient to study the oxidation occurring during individual steps and effects
of additives to minimize oxidation occurring during the processing. Methionine 388 is found
between EGF 4 and 5 of thrombomodulin, and this region is sufficient to activate protein C.
Recombinant fragment EGF 456 of thrombomodulin was expressed using Pichia Pastoris to
produce large quantity of recombinant protein. Fragments of human thrombomodulin were
expressed in the Pichia pastoris expression system. The construction of the P. pastoris
expression system containing the gene TMEGF456 has been described by White et al. [62] and
the expression system was the kind gift of Dr. Komives. The recombinant protein was produced
using P. pastoris strain SMD1168, as this strain lacks protease A. As a result of deficiency of
protease A, this strain is deficient in carboxypeptidase Y and protease B1. Due to absence of
proteases in this strain, the yield is typically much higher. The transformants of this strain can
grow on the histidine deficient medium, since it is defective in dehydrogenase gene (his 4), this
makes selection of transformants easier. The plasmid vector pPIC9K was used for insertion of
synthetic gene for TMEGF456. Along with Met 388, the TMEGF456 fragment expressed in P.
pastoris contains His and Met residues at the N-terminus.
P. pastoris strains were typically grown on YPD-agar plates (2% (w/v) dextrose, 2%
(w/v) peptone, 1% (w/v) yeast extract, and 2% (w/v) agar) or YPD medium (1% (w/v) yeast
extract, 2% (w/v) dextrose, and 2% (w/v) peptone,). Single colony was selected from YPD-agar
plate, and it was inoculated to a sterile flask which contained 10mL solution of YPD. This
culture was placed in a shaker (300 rpm) for 24h at 30 ºC. The YPD solution was centrifuged for
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10 min at 3000 rpm using Sorvall GS-3 rotor. The cells were collected and resuspended in YPD
solution containing 15% glycerol, and aliquots of 1 mL were placed in sterile 1.5 eppendorf
tubes. The tubes were flash frozen using liquid nitrogen and stored at -80 ºC, these ‘stocks’ were
used to inoculate the fresh cultures. The selection of a single colony, inoculation of YPD
solution, and preparation of storage of ‘stocks’ was done by Dr. Jeffery Froude, a former
graduate student from our lab.
4 L of BMGY media was prepared. The BMGY media had composition of 1% (w/v)
ammonium sulfate, 1% (w/v) casamino acids, 3.4 g/L yeast nitrogen base (without ammonium
sulfate and amino acids), 2 mL/L biotin solution, 2% (v/v) 1 M potassium phosphate buffer pH
6.0 and 1% (v/v) glycerol. The BMGY solution was sterilized by passing though the 0.2 µm
bottle top filter. The 0.2 g/L of stock solution of biotin was prepared by dissolving in 0.02 M
potassium hydroxide solution, and passing it through 0.2 µm PES filter, and were stored in -20
ºC. 2 L culture flasks were covered with four layers of cheese cloth and two layers of aluminum
foil, and were autoclaved for 30 min at 121 ºC. Approximately 320 mL of sterilized BMGY
media were aseptically transferred to the 2 L sterile flasks.
A sterile 150 mL baffled flask was used to prepare the starter culture of P. pastoris. 10
mL of sterile BMGY media and 2 mL of frozen stock culture was added to the flask, and was
placed in a shaker (3000 rpm) at 30 ºC for 12 hrs. 1mL of starter culture was added to the 2 L
culture flasks containing BMGY media. After 24 hrs of growth, the aluminum foil was removed
from the culture flasks, cheese cloth was not removed, and was continued to incubate for
additional 24 hrs. Following 2 days of incubation, the culture was transferred to 400 mL
centrifuge bottles and centrifuged at 2500 rpm for 10 min using Sorvall GS-3 rotor. The
supernatant was discarded, and the cell pellets were redissolved in BMMY media. BMMY media
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composition is identical to BMGY, except 2 % methanol is used instead of 1 % glycerol. The
BMMY suspended cells were placed in the culture flask and covered with four layers of
cheesecloth. The flasks were incubated in the shaker (300 rpm, 30 ºC) for 36 hrs. Upon
completion of the induction phase, the culture was centrifuged at 3000 rpm for 45 min. The
supernatant was collected and disodium EDTA was added to make the final concentration 5 mM.
The supernatant was passed through the 0.22 µm bottle top filter to remove the particulates. A
prefilter was used along with the bottle top filter to prevent the premature clogging of the 0.2 µm
filter.
The purification of the supernatant was based on anion exchange chromatography using
Q-sepharose FF. The pH of the supernatant was adjusted to 6.5 by addition of sodium hydroxide.
This step is crucial for the TMEGF456 to bind to the anion exchange column. Two buffers were
prepared for the ion exchange, buffer A (50 mM Tris, 1 mM EDTA) and buffer B (50 mM Tris,
1M NaCl, and 1 mM EDTA). The anion exchange column was prepared by packing q-sepharose
FF into an empty 200 mL glass column. 40 mL bed volume of q-sepharose ff was loaded into the
glass column. The column was attached to the FMI pump attached with solvent inline filter. The
column was equilibrated with 5 bed volumes of buffer A. The flow rate was set to 5 mL/min.
Following equilibration the filtered supernatant was passed through the column at the rate of
5mL/min. Since this part of the procedure took several hours to complete, the ion exchange was
performed in the cold room at 4 ºC. The column was washed with 3 column volumes of buffer A.
The TMEGF456 was eluted by step gradient with buffer B through the column. The proteins
eluted after the gradient was changed to 30% buffer B. The fractions containing TMEGF456
were verified using protein C activation assay. The active fragments were concentrated down to
2 mL volume using Centricon plus-70 centrifugal filter units with 10 kDa molecular weight
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cutoff (Millipore). The concentrated fractions were injected into a reverse phase Waters HPLC
system. The HPLC system contained Vydac dC18, 5 μm particle, 300 Å 4.6x250 mm column
held at 58 °C. Upon injection, a gradient is run at flow rate of 1 mL/min from 10 to 26%
acetonitrile, 0.1 % trifluroacetic acid over 8 minutes, followed by 26% to 40% acetonitrile over
the next 14 minutes and finally from 40% to 90% over the next 25 minutes.

Results and Discussion:
Purification of thrombomodulin
Thrombomodulin is anchored on the luminal surface of the endothelium and as
previously indicated, thrombomodulin lacking the cytoplasmic domain appeared normal.
Thrombomodulin undergoes endocytosis and degradation, and a significant amount of it is
cleaved off and it is found in blood. The concentration of thrombomodulin in serum and plasma
are reported to be between 3 to 300 ng/mL [84]. The thrombomodulin is removed through urine.
Several groups have previously developed methods to isolate thrombomodulin from urine. The
methods they developed were not intended for repeated and rapid purification of
thrombomodulin from urine. They also used large volumes of pooled urine sample to isolate
thrombomodulin, for example, Jackson et al, started from 38 L of urine to isolate
thrombomodulin. The previously developed methods were not applicable for our study, since we
needed quick method of thrombomodulin isolation from urine. The need for rapid processing
stems for our need to prevent oxidation occurring during processing and also to compare levels
of oxidation occurring in different individuals.
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Thrombomodulin concentration in urine was assayed by using IMUBIND
Thrombomodulin ELISA kit by American Diagnostica Inc. This is a sandwich ELISA which
employs two monoclonal antibodies, first antibody recognizes the EGF1-EGF2 region of
thrombomodulin, and second antibody recognizes EGF5-EGF6 region. At the end of the assay,
the concentrations of thrombomodulin were determined by measuring the solution absorbance at
450 nm using a Safire microplate reader by Tecan. Typical volume of morning urine obtained
from a donor was 200-500 mL. The urine from the morning was chosen since they have more
volume, and they are higher concentration of thrombomodulin. The average concentration of
thrombomodulin in urine before any processing was 3-8 ng/ml, based on ELISA assay.
As mentioned in the materials and methods section, several methods were tested for purification
of thrombomodulin from urine prior to purification using HPLC. Regardless of the method, after
collection, urine samples were cooled in 4 °C for no more than 2 hours, and centrifuged in
Sorvall GS-3 rotor at 4,000 rpm for 30 min at 4 °C. The samples were stored at 4 °C because the
cooling produces precipitate.
Tangential flow filtration (TFF) System
Labscale Tangential Flow Filtration (TFF) System, manufactured by Millipore, was
tested for the concentration of the urine sample. In regular filtration, particles that are too big to
pass through the membrane are retained on the membrane surface, and small particles pass
through the membrane. As the filtration progresses, the large particles accumulate on the surface
of the membrane, this lowers the surface area of the membrane, and small particles do not pass
through the membrane. In TFF system, solution is pumped tangentially along the surface of the
membrane, unlike normal filtration where the flow of the solution is normal to the plane of the
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membrane. The applied pressure forces the smaller molecules through the filter and the
molecules that are too big to pass through the membrane are swept away by the tangential flow.
Jumbosep spin filter
Jumbosep spin filters were tested for the concentration of the urine sample. The
Jumbosep centrifugal device (Pall) consists of sample reservoir, membrane filter insert, and the
filtrate receiver. The membrane filters are constructed from modified polyethersulfone on
polyethylene substrate, and they are low protein binding. A membrane filter with molecular
weight cut off of 30 kd was used for purification. The urine sample that was previously cooled at
4 °C was concentrated followed by buffer exchange, passed through SP Sepharose FF and Q
Sepharose FF, and thrombomodulin was eluted. We compared the amount of thrombomodulin
retained in the concentrate after the purification using Jumbosep and TFF system. The urine
sample was split into two equal parts and they were run simultaneously. The ELSIA test showed
that there was ten times higher concentration of thrombomodulin in retentate from Jumbosep
compared to TFF system. We did not incorporate the concentration step in our final purification
method, however if we incorporate a concentration step in the future, we will use Jumbosep.
Q sepharose purification
The urine sample that was cooled at 4 °C and centrifuged in Sorvall GS-3 was passed
through the polyethersulfone 0.2 µm bottle top vacuum filter from corning. These hydrophilic
filters are low binding to proteins and they remove particulates during filtration. The removal of
particulates is necessary prior to the downstream ion exchange; their presence will clog the Q
Sepharose column and lower the column life. Ideally, buffer exchange would be an appropriate
step for the urine sample to undergo so the ionic strength of the various samples is constant.
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Buffer exchange with high volumes of samples would be time consuming; instead 0.25 M
imidazole acetate at pH 6.0 was added to make final concentration 25 mM imidazole acetate.
Thrombomodulin is a very acidic protein; the pI of the protein is approximately 4.8. The pH of
the urine sample was adjusted to 6.0 to make the protein negatively charged. Next, the urine
sample was passed through a 50 mL Bio-Rad column containing 20 mL bed volume of Q
Sepharose FF using FMI pump. The column was previously equilibrated with 3 bed volumes of
25 mM imidazole acetate at pH 6.0. The negatively charged proteins along with thrombomodulin
bind to the ion exchange column. As previously mentioned, thrombomodulin is not found intact
in urine, instead it is fragmented. Fortunately, all the thrombomodulin fragments are uniformly
acidic throughout its length, making the ion exchange purification of its various fragments
simple. The column is washed with 25 mM imidazole acetate at pH 6.0, and proteins are eluted
using 25 mM imidazole acetate, 50 mM NaCl at pH 6.0, and 25 mM imidazole acetate, 0.5 M
NaCl at pH 6.0. Eluents following the addition of 25 mM imidazole acetate buffer, pH 6.0, 0.5 M
NaCl was collected in 15 mL conical tube, 5 mL in each tube. 15 mL eluent, after addition of 25
mL of 25 mM imidazole acetate buffer, pH 6.0, 0.5 M NaCl, tested positive for thrombomodulin.
Solution of 0.2 M L-methionine was added to thrombomodulin containing fractions to make final
concentration 2 mM methionine. Methionine was added as a sacrificial molecule to absorb
oxidants that might be occurring during the downstream processing. The thrombomodulin
containing fractions dried using medium heat, under vacuum, using the SpeedVac concentrator
system. The SpeedVac surface that was accessible to light was covered with aluminum foil to
prevent photooxidation. The dried samples were reconstituted into 18.2 megaohm pure water.
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Reverse phase HPLC purification
Thrombomodulin containing fragments from Q Sepharose were dried using SpeedVac
under vacuum, and reconstituted in 18.2 megaohm pure water, passed though the 0.2 µM spin
filter, and were injected into the HPLC. A shows the HPLC chromatogram obtained from the
injection of 1.4 mL sample of 27 year old male donor. Figure 2.2 B is the magnification of
Figure 2.2 A, and it spans the area where thrombomodulin elutes, namely at 30 minute. The total
amount of thrombomodulin isolated from a single urine sample after the HPLC purification was
0.05–0.1 µg, which is not sufficient to compare the relative oxidation of methionine 388
oxidation. Multiple urine samples were collected from an individual donor to increase the
amount thrombomodulin collected following HPLC purification. Typically 2-3 urine samples
were collected from a donor within consecutive days, 0.15-0.25 µg thrombomodulin was
collected after the samples were pooled.
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Figure 2.2 A&B: Final purification of thrombomodulin by reverse phase HPLC. The following
sample, a final purification of a male non-smoker urinary thrombomodulin, contained
thrombomodulin in the peak at 30 minute. Figure 2.2 B is a selected area from Figure 2.2 A.

45

Oxidation during processing
Oxidation that could be occurring during the purification of thrombomodulin has always
been a concern. Several steps were taken to minimize the oxidation that was occurring during
processing. During the lyophilization step, the samples were shielded from light to prevent photo
oxidation of methionine. The transparent regions of the speedvac were covered with aluminum
foil. Thiodiglycol was added to the urine samples prior to collection. It was added as a scavenger
molecule to prevent methionine oxidation. 5 mL of thiodiglycol was added to the centrifuge
bottle before the samples were collected. 1 mL of 0.5 M EDTA pH 8.0 was added to the
centrifuge bottles prior to urine collection. EDTA is a chelator[155], and it has been shown to
slow Fenton oxidation[156, 157]. Following the elution of thrombomodulin from the Qsepharose FF column and reverse phase HPLC, free methionine was added to make the final
concentration to 2 mM. This was added as sacrificial molecule to prevent oxidation of
methionine 388 during processing.
Final method for the purification of thrombomodulin
The urine sample was cooled at 4 °C, centrifuged in Sorvall GS-3, and passed through the
polyethersulfone 0.2 µm bottle top vacuum filter. The pH of the sample was adjusted to 6.0, and
the sample was passed through a column containing 20 mL bed volume of Q Sepharose FF. The
protein was eluted using NaCl gradient, and dried under vacuum, and injected into the reverse
phase HPLC. There was ten times the amount of thrombomodulin retained after the purification
using Jumbosep compared to TFF system. The purification using 20 mL bed volume of Q
Sepharose FF purified 1.5 fold more thrombomodulin compared to Jumbosep, however Q
Sepharose FF was without any preconcentration step. Besides the low yield of thrombomodulin,
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the concentration using Jumbosep or TFF was also accompanied by other drawbacks. The
purification and buffer exchange of 400 mL of urine sample required on average 6 hours, which
increased the likelihood of our protein being oxidized. Also, it required frequent buffer changes
and manipulation of the sample, so was quite labor intensive. On the other hand, the processing
time using Q Sepharose FF typically was just 2-3 hours and, equally importantly, gave a higher
yield of thrombomodulin.

Digestion of thrombomodulin
The linear chains of amino acids fold into a specific structure to carry out their functions.
The folded protein in its native state is stable under physiological conditions. The forces behind
the 3D folded structure of proteins are following: 1) Hydrogen bonds [158]. 2) Van der Waals
interactions. 3) Backbone angle preferences. 4) Electrostatic interactions. 5) Hydrophobic
interactions [159-161]. Collectively these forces can be referred to as forcefields [162]. In order
for a protein to undergo complete digestion, the forcefield associated with the folded protein
must be disrupted to unfold the protein. The folded protein imposes steric hindrance to the
protease, as a result the protease is unable to access and ultimately cleave the protein. In most
proteomics studies it is assumed that the digestion of proteins is driven to completion, and such
assumption is correct for most proteins. However, many proteins are resistant to proteolysis, and
they do not undergo complete digestion. There are several factors that affect the protein
digestion, including but not limited to ineffective denaturation due to poor protein solvation, lack
of localization of enzyme, short reaction time, and the competing presence of other proteins in
the digestion [163]. Effective digestion of purified thrombomodulin was crucial to quantify the
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reduced and the oxidized peptides ratios to quantify the methionine oxidation. We monitored the
degree of thrombomodulin digestion by chymotrypsin by injecting the digested sample into the
HPLC. The degree of digestion was calculated by comparing the area of the peak occupied by
thrombomodulin in HPLC chromatogram before and after chymotrypsin digestion (Figure 2.3).
Digestion using manufacturer’s protocol
Using the manufacturer’s protocol in which the HPLC purified dried thrombomodulin
fraction was reconstituted in minimal volume of 200 mM Tris-HCl pH 8.0, reduced using TCEP,
deglycosylated, and digested for 2 hrs using 4 Units of chymotrypsin dissolved in 50 mM TrisHCl, 1mM CaCl2, pH 8.0 only digested 15 % of the total thrombomodulin. Until this point, we
were under the assumption that the digestion using chymotrypsin went to completion, hence we
focused towards creating a method in the Acquity UPLC that would provide a PDA
chromatogram that gave us resolved oxidized and the reduced peaks following digestion of
thrombomodulin. Little did we know, only 15% of the thrombomodulin underwent complete
digestion after 2 hr reaction with chymotrypsin (Figure 2.3). Following this discovery, the
priority for this project was to create a digestion method that would effectively digest
thrombomodulin to the extent that would allow us to detect the oxidized and the reduced forms
of peptide using the quantification of methionine techniques that will be discussed further in this
chapter.
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Figure 2.3 A&B: HPLC chromatogram of purified thrombomodulin prior to chymotrypsin
digestion (A). HPLC chromatogram of 2 hr chymotrypsin digested thrombomodulin (B). Two
chromatograms were used to monitor the extent of digestion. The efficiency of various digestion
protocols were tested using this method.
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Digestion using urea
Protein digestion using urea is still the most widely used technique to solubilize proteins
in a solution digestion. The mechanism of protein denaturation by urea is believed to begin with
attachments of urea to histidine, and then to the amide groups and positively charged amino acid
and, which results in disruption of the hydrogen bonds, followed by water and urea solvation
[164, 165]. Over the time, urea in water releases isocynate, which can carbamylate primary
amines, hence urea was freshly prepared. Also, upon heating, urea can degrade into ammonium
cyanate, which can lead to the carbamylation of the primary amines. Based on the
manufacturer’s manual, chymotrypsin retains 100% enzymatic activity in up to 4M urea. In the
experiments where 8M urea was used, the concentration of the urea was halved by dilution using
the appropriate buffer prior to addition of chymotrypsin. The thrombomodulin digestion using
2.5 M and 8 M urea did not enhance the digestion compared to the initial method.
Digestion using acetonitrile
Changing the solvent in which the digestion is probably the most convenient way to
facilitate the solubilization of the protein, and increased solubility can potentially increase the
rate of digestion by protease. Trypsin digestion of protein in acetonitrile has been used in some
proteomics studies [166, 167]. Trypsin digestion was conducted on myoglobin and chicken
ovalbumin using organic solvent [167]. These proteins are resistant to proteolysis unless they are
subjected to thermal or chemical denaturation prior to digestion. These proteins are easily
digested in organic solvent, efficient digestion occurred within 5 min [167]. The autolysis of the
protease is a concern when using organic solvents, but the proteolytic activity of trypsin is not
affected even in 80% acetonitrile solution. Also, since these protocols did not use chaotropes or
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surfactants, it makes downstream MS or HPLC analysis easier. The use of chymotrypsin to
digest thrombomodulin in an organic solvent was attempted achieve complete digestion.
Chymotrypsin in water miscible organic solvents like methanol, ethanol, 1-propanol, 2-propanol
and acetonitrile shows enhanced stability and catalytic activity [168]. In the presence of 20%
acetonitrile in buffer, the enzyme activity of chymotrypsin increased up to 6 fold. Accordingly,
thrombomodulin was dissolved in acetonitrile in 50 mM Tris-HCl/10 mM CaCl2, pH 8.0 buffer.
Multiple experiments where the concentration range of acetonitrile was varied between 20%50% were conducted. Unfortunately, this method did not enhance the digestion compared to the
initial method.
Digestion using Invitrosol
Invitrosol is a proprietary surfactant from Invitrogen. It keeps hydrophobic proteins in the
solution and it has no effect on the activity of protease. More importantly, it is compatible with
HPLC and MS analysis, unlike most surfactants that interfere with such instruments. The use of
Invitrosol to enhance the digestion of thrombomodulin from urine did not result in significant
improvement in digestion. Experiments using organic solvent along with Invitrosol did not
enhance the digestion compared to the initial method.
Digestion using RapiGest
RapiGest SF is an acid labile surfactant. It can be immediately be degraded from solution
by addition of acid. It decomposes into dodeca-2-one and sodium-3-(2,3-dihydropropoxy)
propanesulfonate. The first product is insoluble in water and second is highly soluble in water, so
it is not retained in reverse phase HPLC. This feature makes the use of this surfactant attractive,
since it does not interfere with the downstream analysis like HPLC and MS. RapiGest SF
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improves solubility of protein in a solution and is an enzyme friendly surfactant for in-solution
protein digestion. Proteases are resistant to denaturation in RapiGest SF solution. Trypsin has
100% activity in 0.1% RapiGest SF solution, and 87% activity in 0.5% RapiGest solution[169].
The proteins unfold in RapiGest SF solution and the proteolytic sites are exposed for digestion.
The globular proteins, which are typically difficult to digest, can be digested within minutes
using RapiGest SF [170]. This surfactant also aids in deglycosylation of proteins. However, the
use of RapiGest SF to digest the thrombomodulin isolated from urine did not enhance the
digestion compared to the initial method.
Digestion using EDTA
The thrombomodulin EGF domains 5 and 6 are the primary binding site for thrombin
[171, 172], while EGF4 of thrombomodulin is necessary for the thrombin-thrombomodulin
mediated protein C activation [173, 174]. In studies using recombinant thrombomodulin, the
thrombin-thrombomodulin mediated activation of protein C shows a bell shaped dependence on
Ca2+ concentration. Ca2+ binds to EGF3 and EGF6 region of thrombomodulin, the binding
affinity is almost 15 fold higher in the EGF6 region based on Ca2+ analysis of dialyzed
recombinant thrombomodulin [175]. There is a higher proportion of β-sheet and more structured
conformation seen in the EGF domains that are saturated with Ca2+. The ordered conformation
resulted in decreased efficiency of trypsin to cleave the C-loop of EGF6. We alternatively
hypothesized the partial digestion of thrombomodulin might be due to Ca2+ stabilization.
Proteins can be converted into apoproteins by addition of chelators like EDTA and
EGTA. Ca2+ binds to thrombomodulin EGF3 and EGF6, and the binding of Ca2+ results in
formation of secondary structures in these regions. The stabilization induced by Ca2+ binding is
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known to make thrombomodulin resistant to protease digestion [175]. The simple method to
expedite the digestion of thrombomodulin might be by removal of Ca2+. Thrombomodulin
purified from urine was digested using chymotrypsin in presence of 10 mM EDTA. Upon
completion of digestion, the digested sample was injected into reverse phase HPLC to assess the
degree of digestion. The HPLC peaks corresponding to thrombomodulin were no longer seen in
the chromatogram, indicating complete digestion of thrombomodulin. Sample of digested
thrombomodulin in presence of EDTA was sent for MS analysis. The MS did not identify
peptides corresponding to 1562 or 1578 m/z. The results were puzzling, HPLC indicated the
digestion had gone to completion; however MS did not confirm the presence of the methionine
388 containing peptide. The experiment were repeated several times, however the results
consistently remained the same. The results were puzzling until we found the following paper,
“The CBP/p300 TAZ1 domain in its native state is not a binding partner of MDM2” [176].
Zinc-binding proteins comprise one of the largest classes of protein and they are very important
for the gene expression. This class of protein includes transcription factors of the DNA, coactivators, RNA polymerase and chromatin-modifying and -remodeling enzymes [177]. Many
zinc-binding proteins need Zn2+ to fold into their 3D structure, and for participation in their
intermolecular interactions. In the mentioned study [176], the zinc domain of transcriptional
proteins CBP (CREB-binding protein) and p300 were studied. The zinc binding domain when
treated with EDTA resulted in denaturation of the protein. They attempted to restore the native
structure of the protein by addition of excess Zn2+ following EDTA denaturation, this did not
result in refolding of the protein, suggesting irreversible denaturation by EDTA. More
significantly, their results showed that under EDTA induced denaturation the proteins formed
non specific interactions resulting in aggregation of proteins. They concluded that the EDTA
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mediated denaturation leads to irreversible denaturation and aggregation of the proteins. Based
on these findings, we believe that EDTA induced denaturation and aggregation resulted in
disappearance of thrombomodulin peak in the HPLC chromatogram. The pursuit of
thrombomodulin digestion using EDTA was discontinued.
Final method for the digestion of thrombomodulin
The dried thrombomodulin containing fractions from the reverse phase chromatography
were pooled and dissolved in approximately 100 uL of 1X phosphate buffered saline (PBS). The
samples that were cloudy prior to digestion were spun in a microcentrifuge (Galaxy 14D VWR)
at 13K RPM for a minute. This undissolved material proved to contain the bulk of the
thrombomodulin. Fortunately, after the supernatant was removed, the precipitate readily
dissolved in 75 µL of 1X PBS. Fresh tris-carboxyethylphosphine (TCEP) was added to make the
final concentration of 50 mM TCEP. 10 µL of 0.5 M sodium phosphate buffer pH 7.5 added to
the sample, prior to addition of 500 units of PNGase F (New England Biolabs). The samples
were incubated at 37°C for 4 hours to deglycosylate the sample. The protein was then digested at
30°C for 8 hours after adding 4.1 μg of sequencing grade chymotrypsin (Princeton Separations)
dissolved in 50 mM Tris-HCl, 1mM CaCl2, pH 8.0. The chymotrypsin was inactivated by
placing the samples in a 100°C dry bath for 30 seconds. This method achieved thrombomodulin
digestion which resulted in detection of both reduced and oxidized peptides by MALDI-TOF.
This method was incorporated into the final purification and qualitative analysis of
thrombomodulin.
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Quantification of methionine oxidation
The quantification of urinary thrombomodulin methionine 388 oxidation involves 3 three
major steps: 1) purification of thrombomodulin from urine, 2) digestion of purified
thrombomodulin 3) quantification of methionine oxidation. We have discussed the first two
steps, in this section we will discuss the methods attempted to complete the final step.
Alkylation of cysteine by fluorescent reagent
Cysteine is the most reactive residue commonly found in proteins and peptides. In its
unprotonated state, the thiol group is strong nucleophile and will react with a wide variety of
reagents. The alkylation of cysteine side chain was attempted for two reasons. First, the
alkylation of cysteine prevents reformation of disulfide bonds which subsequently prevents the
formation of the secondary structure hence protein remains in the denatured state. And second,
our hope was to introduce a fluorescent reporter group on the peptide APIPHEPHRCQMF.
Several peptides are formed when thrombomodulin is digested by chymotrypsin, not all of these
peptides have cysteine. Only the peptides that have cysteine will have the covalently bonded
fluorescent reporter group, when the digested and alkylated sample is injected into an HPLC
with fluorescent detector, only the fluorophores will be detected by the detector. The attachment
of fluorophore eliminates the noise from non fluorophore peptides, and in theory would increase
the resolution and sensitivity of detection of the oxidized and the reduced peptide.
Reaction of the sulfhydryl group of cysteine with α-haloacids or their amide derivatives is
the most common method used to alkylate cysteine. The iodo compounds is preferred over other
halides since iodide is a much better leaving group, hence the reaction is much faster. 5-((((2iodoacetyl)amino)ethyl)amino)naphthalene-1-sulfonic acid (1,5-IAEDANS) [150] was used for
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alkylation of cysteine in thrombomodulin. Reaction of a cysteine side chain with 1, 5 IEADANS
produces dansylated cysteine on the protein (Figure 2.4). 1, 5-IAEDANS has a peak excitation
wavelength of 336 nm and a peak emission wavelength of 490 nm. The extinction coefficient of
the dye is 5700.

Figure 2.4: Alkylation of cysteine using 1, 5-IAEDANS.

Before attempting to alkylate the cysteine residues in thrombomodulin, the alkylation
using 1, 5-IAEDANS was attempted in the synthetic peptide APIPHEPHRCQMF. The 2 µL of
10 mg/mL synthetic peptide stock solution was dissolved in 198 µL 0.1 M Tris-Cl pH 8.0
containing 50 mM freshly prepared tris-carboxyethylphosphine (TCEP). The sample was
incubated, and 5 fold molar excess (over total thiols) of freshly prepared 1, 5-IAEDANS was
added. Nitrogen was flushed over the surface of the liquid and the microcentrifuge tube was
sealed. The sample was incubated for > 4 hrs at 37 °C. Following alkylation, 10 fold molar
excess of 2-mercaptoethanol (2-ME) over 1,5-IAEDANS was added to the sample [154]. The
sample was injected into the Waters ACQUITY UPLC System, BEH 130 C18 1.7 µm 2.1x150
mm column, and Fluorescence (FLR) detector (excitation wavelength 340 nm, and emission
wavelength 490 nm). The methionine and methionine sulfoxide forms of the peptide
APIPHEPHRCQMF eluted at 2.25 and 2.5 minutes, respectively. The alkylated oxidized and
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reduced peptides eluted at 2.35 and 2.6 minutes, respectively. Figure 2.5 is a UPLC
chromatogram of 4 µL injection of 0.1 µg/µL synthetic peptide alkylated using 1, 5-IAEDANS
for 16 hrs at 37 °C, and Figure 2.6 is UPLC FLR chromatogram of the same injection.
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Figure 2.5: Acquity UPLC chromatogram of IAEDANS labeled synthetic APIPHEPHRCQMF
and APIPHEPHRCQMoxF at 214nm. Two forms of non alkylated peptide APIPHEPHRCQMF
eluted at 2.25 and 2.5 minutes, respectively. The alkylated oxidized and reduced peptides eluted
at 2.35 and 2.6 minutes, respectively.
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The cysteine alkylation by 1,5-IAEDANS was attempted on urinary thrombomodulin
purified by HPLC. The protocol used to alkylate the synthetic peptide was used to alkylate the
purified thrombomodulin. The alkylated thrombomodulin was digested using chymotrypsin, and
subsequently injected into the Acquity UPLC. Based on alkylation experiments performed using
the synthetic peptide, the elution time of the alkylated oxidized and the reduced peptide was
discovered. The FLR detector did not detect alkylated oxidized and the reduced peptide
following alkylation using 1,5-IAEDANS and digestion using chymotrypsin. We hypothesized
the absence of the alkylated peptides in FLR chromatogram resulted from ineffective alkylation,
which was mostly likely due to stubbornness of thrombomodulin to denature. This method was
not incorporated in quantification of methionine 388 oxidation, because significant alkylation of
thrombomodulin could not be achieved that would produce alkylated peptide FLR signal. In
retrospect, the difficulty may have been the lack of digestion of thrombomodulin, so revisiting
this labeling procedure may be worthwhile.
Determination of methionine 388 oxidation by UPLC
Acquity UPLC offers increased resolution, sensitivity and speed compared to HPLC. It
uses small particle columns (1.7 µm – 1.8 µm), which improves system efficiency by producing
better resolution, and also lowering the analysis time. This system is designed to minimize band
spreading resulting from the column and also from the instrument. Several UPLC methods were
developed to separate the synthetic peptide mixture (APIPHEPHRCQMoxF and
APIPHEPHRCQMF). New methods were created by changing the gradient, temperature, flow
rate, and column. After numerous experiments we developed our most effective UPLC method
for purification. Using this method the oxidized and the reduced peptides in the synthetic peptide
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mixture eluted at 12 and 21 minute respectively, they were 9 minutes apart from each other
( Figure 2.7).

Figure

2.7:
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of

the
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APIPHEPHRCQM(ox)F elutes at 12 min and APIPHEPHRCQMF elutes at 21 min.
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mixture.

The ratio of oxidized and reduced peptide within the synthetic peptide can be calculated
using the UPLC chromatogram simply by the dividing the area occupied by the oxidized by area
occupied by the reduced peptide. Using this approach we should able to calculate the ratio of the
reduced and the oxidized peptide in a chymotrypsin digested thrombomodulin sample. The ratio
of reduced and the oxidized peptide within a sample is equivalent to the ratio of reduced and the
oxidized methionine in a sample of thrombomodulin purified from urine.
The HPLC purified dried thrombomodulin following chymotrypsin digestion using was
injected in the UPLC. The elution of the oxidized and the reduced peptide was mapped using the
synthetic peptides, they elute at 12 and 21 min respectively. Figure 2.8 is UPLC chromatogram
of 25 µL injection of chymotrypsin digested thrombomodulin of 26 year old non smoker donor.
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Figure 2.8: UPLC chromatogram of chymotrypsin digested urinary thrombomodulin of 26 year
old non smoker donor.
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Figure 2.9: Overlay of UPLC chromatograms. Top chromatogram is of chymotrypsin digested
urinary thrombomodulin of a 26 year old Caucasian male non smoker, and the bottom
chromatogram is of synthetic peptide mixture.
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Figure 2.9 is overlay of UPLC PDA chromatogram of chymotrypsin digested urinary
thrombomodulin and synthetic peptide mixture. As seen in the figure the oxidized and the
reduced peaks of the chymotrypsin digested urinary thrombomodulin is not resolved, especially
the oxidized peptide. Much time and resources were devoted to develop methods to resolve the
two peaks, however the resolution necessary to calculate the relative area occupied by the
reduced and the oxidized peaks could not be achieved.

Figure 2.10: MALDI-TOF spectra of chymotrypsin digested thrombomodulin purified from
urine. The sample was collected from a 28 year old male smoker. The oxidized and the reduced
forms of peptide are present in this sample.
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Mass spectrometry analysis of methionine 388 oxidation
Matrix-assisted laser desorption ionization (MALDI) is a powerful technique for mass
spectrometry of peptides and proteins [178]. This technique provides fast and accurate
acquisition of molecular mass and purity. The digested thrombomodulin was sent for MALDI
analysis in Mass Spectrometry Facility located at the University of Arkansas. Figure 2.10 is
MALDI-TOF spectra of chymotrypsin digested urinary thrombomodulin from a 28 year old male
smoker. The isotopically averaged mass of reduced (APIPHEPHRCQMF) and oxidized
(APIPHEPHRCQMoxF) peptides is 1562.73 and 1578.74 Da respectively. Both forms of
peptides were detected by MALDI-TOF, and the intensity of the oxidized peptide was three fold
more compared to its counterpart. This technique can be used for semi-quantitative test for the
two forms of peptide.
Final method for the quantification of methionine 388 oxidation
The chymotrypsin digested thrombomodulin alkylation using 1,5-IAEDANS did not
result in sufficient alkylation of the peptides, and they could not be visualized in the FLR
detector. Separation of reduced and the oxidized peptides using Acquity UPLC could not
produce sufficient resolution to quantify the oxidation of methionine. The MALDI TOF injection
of digested thrombomodulin confirmed the presence of two forms of peptides and also provided
their relative intensities. This intensity of the peptides was used for the quantification of the
methionine oxidation, the details of this method will be covered in the following chapter.
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Conclusion
In this chapter we have discussed techniques that were used to for 1) purification of
thrombomodulin from urine, 2) digestion of purified thrombomodulin 3) quantification of
methionine oxidation. The cooled urine sample centrifuged in a Sorvall GS-3 rotor, filtered using
0.22 µm PES membrane filter, passed through Q Sepharose FF, and reverse phase HPLC
provided maximum yield. The digestion of purified thrombomodulin where the samples were
washed in 1XPBS buffer prior to addition of chymotrypsin was the most successful compared to
other methods. The fluorophore and Acquity UPLC system could not be used for quantification
of methionine oxidation. MALDI-TOF was used for quantification of methionine oxidation; this
topic will be discussed in detail in chapter 3. This procedure works well, but it is worth
considering how it might be improved in the future.
Oxidation that might be occurring during the purification of thrombomodulin would not
invalidate a finding that one population had a higher level of oxidation than another, but would
complicate comparison of absolute levels of oxidation. Based on oxidation experiments using
synthetic peptide, we believe significant oxidation is not occurring during processing. A 300 uL
of synthetic peptide APIPHEPHRCQMF was divided into three 100uL aliquots, the first aliquot
was control. The second aliquot was dried under medium heat (45°C) for 4 hours in SpeedVac,
and upon drying the synthetic peptide was reconstituted in distilled water to make the final
volume 100 uL. The third 100 uL aliquot was allowed to sit in room temperature for 4 hours,
which is the time samples are subjected to chymotrypsin digestion and which is also
approximately the time it takes for a sample to be centrifuged and passed through the Q
Sepharose FF column. All three samples were separately injected into the Acquity UPLC and the
ratio of oxidized and the reduced form of APIPHEPHRCQMF for each sample was calculated.
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The ratio of reduced and oxidized peptide remained constant in all three samples. The calculation
was performed comparing the relative area occupied by reduced and oxidized peak in the UPLC
PDA chromatogram at 214nm.
Although this experiment was reassuring, steps were taken to minimize oxidation of
protein during processing. During the lyophilization step, the samples were shielded from light to
prevent photo oxidation of methionine. Thiodiglycol was added to the urine samples prior to
collection. Thiodiglycol was added as a scavenger molecule to minimize methionine oxidation
[179, 180]; it was added to the urine sample container before collection. EDTA was also added
to the sample container prior to urine collection. EDTA is a chelator [155, 181], and it has been
shown to slow Fenton oxidation [156, 157], and would also inactivate any metal dependent
proteases that might be present[182, 183]. Following the elution of thrombomodulin from the Qsepharose FF column and reverse phase HPLC, free methionine was added as a sacrificial
molecule to minimize oxidation. None of these additives used to minimize oxidation were used
for the synthetic peptide oxidation experiments. Oxidation of synthetic peptide dissolved in
water may not mimic the behavior of protein in urine, because latter is a complex solution
composed of cells, proteins and salts. However, the methionine in the synthetic peptide is fully
exposed to the solvent, and methionine 388 in thrombomodulin is partly buried in the protein’s
hydrophobic core, which might make it less susceptible to oxidation than the synthetic peptide.
While we are reasonably confident that oxidation of the protein is not occurring, experimental
proof of this would be useful.
In the future, experiments can be designed to test the competency of each of the
mentioned steps to minimize oxidation during processing. It is possible to produce large
quantities of the recombinant TMEGF 456 using Pichia pastoris. As previously mentioned,
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methionine 388 is found between EGF 4 and 5 of thrombomodulin. The recombinant TMEGF
456 could be subjected to the urine purification protocol. Recombinant TMEGF 456 could be
purified containing only single additives, followed by purification using all additives. The
recombinant TMEGF 456 purified without any additives would serve as the control. Successful
completion of this experiment will tell us the approximate oxidation that occurs during the
processing of urine sample. It should be pointed out that the minimization of oxidation during the
processing would be advantageous for this research; however, it is not critical for its success.
Since all the urine samples are subjected to the same purification method, the oxidation that
could be occurring during processing should be the similar for all of them. When the methionine
oxidation levels in smokers and non smokers are calculated, the oxidation that occurred during
their respective purification, assuming they are equal, cancels out each other.
The thrombin affinity chromatography was the very first method used to isolate
thrombomodulin and it has been used in some other studies [184-186]. Dr. Deepika Talla, a
former graduate student in our lab, had examined a method based on thrombin affinity
chromatography. However, this method failed to produce significant thrombomodulin from urine
apparently due to the following reasons. First, papers using thrombin affinity used some other
steps prior or after to finish cleaning up the thrombomodulin, so it was not as simple in practice
as it appears in theory. Second, depending upon the glycosylation state of thrombomodulin there
is variance towards its affinity for thrombin column [187]. Third, and most importantly,
Komives’ group confirmed that thrombomodulin oxidation reduces thrombin affinity by a factor
of 10. [94] In our preliminary work, thrombin affinity columns, even used in fairly large excess,
“leaked” some thrombomodulin and this thrombomodulin was presumably more oxidized. This
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method was therefore abandoned. However, might some other form of affinity purification
work?
Antibodies might work, and should be explored in the future. Aptamers are in vitro
selected oligonucleotides that have high affinity and specificity towards their target [188, 189].
They are selected in a process called systematic evolution of ligands by exponential enrichment
(SELEX), selection process involves screening for single stranded oligonucleotides sequences
based on its binding affinity towards the target of interest [189-193]. DNA aptamers that bind to
thrombin have been developed to capture thrombin using affinity phase stationary phase
chromatography [193]. Thrombin was captured on stationary phase that had thrombin aptamer
covalently attached to it. Proteins were loaded into the column, the non specific proteins were
washed and bound thrombin was eluted using 20 mM Tris buffer containing 8 M urea, pH 7.3, at
50 °C. Our current protocol requires 2-3 samples of urine to be collected from each donor to
isolate sufficient thrombomodulin to detect the peptide of interest in MALDI-TOF.
Thrombomodulin binding aptamers could be developed and covalently bound to the stationary
phase to conduct affinity based chromatography. However, the greatest promise of aptamers is
to skip the purification of the protein entirely.
It is possible that aptamer that are specific to each of the oxidized and the reduced forms
of thrombomodulin could be developed. Previously, our group attempted to raise antibodies
specific for the reduced and oxidized forms of thrombomodulin. This was unsuccessful, possibly
because of the high homology in this region of thrombomodulin between different mammalian
species. If successful in developing aptamers for the oxidized and reduced form of
thrombomodulin, one can imagine using them in an ELISA-like test of the amounts of each form
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in urine or blood. Such a test would be a great timesaving device, minimize the chances of
oxidation, and would require much less sample.
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CHAPTER 3: IS METHIONINE 388 OF THROMBOMODULIN MORE OXIDIZED IN
CIGARETTE SMOKERS?
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Introduction
The blood of a smoker is more prone to clot than a non smoker; they are in
hypercoagulable state. The narrowing of the arteries resulting from atherosclerosis increases the
possibility of cardiovascular diseases [111], equally important is the hypercoagulable state seen
in smokers. Cardiovascular diseases are the most common cause of death in smokers. The most
common cardiovascular diseases seen in smokers are myocardial infarction and stroke. The fact
that smokers have a hypercoagulable state has been established [194-197]; however, despite
intensive research the molecular origin of such a state has not been shown. Free radical mediated
oxidative damage to the endothelium is suggested to be an important factor for the development
of cardiovascular diseases in smokers [112]. We hypothesized that oxidation of methionine 388
of thrombomodulin results from smoking. We further hypothesize that oxidation of methionine
388 in thrombomodulin is an important molecular factor leading to cardiovascular diseases in
smokers.
To understand why we feel thrombomodulin oxidation is important, one must first
understand the role of this regulatory protein. Thrombin when bound to thrombomodulin
activates protein C. Activated protein C proteolytically destroys coagulation factors Va and
VIIIa, thus suppressing further thrombin formation. The thrombin- thrombomodulin complex
also activates the carboxypeptidase thrombin-activatable fibrinolysis inhibitor (TAFI) [198]. The
activation of protein C and TAFI inhibits coagulation and fibrinolysis, making thrombomodulin
a key protein for the regulation of coagulation and fibrinolysis.
Thrombomodulin is found on endothelial cell surfaces [55, 56]. It was discovered by
Esmon and Owen in the 1960’s. In rats, it is found predominantly in the lungs when compared
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with other vascular organs like kidney and liver [57]. Thrombomodulin, purified from human
lung endothelial membrane preparations, had an apparent MW of 78,000 Da [55]. Encoded by an
intronless gene, the mature single-chain glycoprotein in the human is 557 amino acids long.
Structurally it has 5 distinct domains. It has a short cytoplasmic tail at the C-terminus, which
anchors thrombomodulin [58]. The deletion of this tail in mice does not have any effect in
development, survival, coagulation and inflammation [58]. There is a well conserved membranespanning domain, followed by a serine/threonine-rich domain with four potential sites for Olinked glycosylation. The serine/threonine region supports the attachment of chondroitin sulfate,
which is has 20 repeating disaccharide units and a terminal trisaccharide unit [59]. Adjacent to
the serine/threonine-rich region is a domain that has 6 epidermal growth factors (EGF)-like
repeats, this domain is the best characterized. This region shows disulfide bonding pattern that is
seen in a typical protein-protein interactions. The first two EGF- like repeats, which are furthest
from the serine/threonine rich region, remain unknown as to their function. EGF-like repeats 3,
4, 5, and 6 [62-64] have been studied in detail by several groups and are essential for activation
of Protein C by the thrombin-thrombomodulin complex. The cofactor function for
thrombomodulin requires the last three of six tandemly repeated EGF-like domains (EGF 4, 5,
and 6), as well as a Ser/Thr-rich domain between EGF-like domain 6 and the transmembrane
domain. The residues 1 through 222 comprises N-terminal region of thrombomodulin, which
constitutes almost half of the extracellular portion of the protein. The residues 155 through 222
of thrombomodulin might be associated with plasma membrane and this region is hydrophobic
[66].
Thrombin binds to thrombomodulin to activate Protein C, which stops clotting by
inactivation of clotting factors V and VIII [68]. The thrombin-thrombomodulin complex
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activates protein C 1,000-fold more when compared to activation of protein C by thrombin alone.
Deficiency in protein C or activated protein C is well established as increasing the risk of
thrombosis [69]. Low levels of thrombomodulin are a well established risk factor for heart
disease. Without a doubt, thrombomodulin plays a key role in slowing or stopping clotting.
It has also been shown that thrombomodulin in complex with thrombin activates
thrombin activatable fibrinolysis inhibitor (TAFI) by 1250 fold [72]. Activated TAFI is a
plasma procarboxypeptidase B that stabilizes clot by down regulating fibrinolysis [76]. Activated
TAFI catalyzes the removal of lysine residues from the C-terminal of fibrin, resulting in
elimination of plasminogen binding site of fibrin, subsequently plasminogen is unable to activate
and prevention of fibrinolysis [79, 80]. This function of thrombomodulin might seem
contradictory to its pro-fibrinolytic function previously discussed, but this highlights that
thrombomodulin is a key regulator in coagulation, since it controls both the formation and
breakdown of clots.
Thrombomodulin is anchored on the luminal surface of the endothelium and as
previously indicated, thrombomodulin lacking the cytoplasmic domain appeared normal.
Thrombomodulin undergoes endocytosis and degradation, but a significant amount of it is
cleaved off and it is found in blood. Thrombomodulin found in blood is heterogeneous in size,
due to differences in glycosylation [81, 82] and proteolysis. Four different fragments have been
isolated from blood and seven fragments ranging in size from 12 to 100kDa after reduction of
disulfides [83] . The concentration of thrombomodulin in serum and plasma are reported to be
between 3 to 300ng/mL [84]. In diseases like diabetes and lupus high levels of thrombomodulin
in plasma have been reported, this is believed to be a good marker for endothelial damage [198].
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Studies have correlated high plasma thrombomodulin levels to be associated with a low risk of
developing coronary heart disease [198].
The fourth and the fifth EGF like domains of thrombomodulin consists of 81 amino acids
in together, and the fifth domain contains most of the residues that bind to thrombin [87]. The
EGF like domain 4 and 5 (TMEGF45) bind to thrombin more tightly than EGF 5 alone.
TMEGF45 is the smallest fragment of thrombomodulin that when bound to thrombin can
activate protein C. Addition of fourth and the fifth EGF-like domains separately, do not activate
protein C, suggesting they work together in activation of protein C [88]. The kcat values for
protein C activation by the thrombin-TMEGF45 complex, calculated by binding kinetic studies
and cofactor activity assays, shows TMEGF45 has full cofactor activity. The EGF like domain
six increases the Km value of thrombomodulin for thrombin by factor of ten, despite not altering
the Kcat value of thrombin-thrombomodulin complex for protein C [89].
The EGF 4 and 5 of thrombomodulin is linked together by three residues, and one of
them is methionine, which is the 388th residue in thrombomodulin (Met388). Met388 in
thrombomodulin is conserved in bovine, mouse and human. The mutation of Met388 to any
other residues, except leucine, decreases the anticoagulant cofactor activity of thrombomodulin
[91]. More importantly, there is 76-90% loss of activity when Met388 is oxidized using H2O2
[92]. There are four other methionine residues found in thrombomodulin, but their oxidation
does not disrupt the ability to activate Protein C [92]. The Kd of thrombomodulin thrombin
interaction increases to 10.9 from 4.4nM, when a full length thrombomodulin had oxidized
Met388 [93]. TMEGF45 with oxidized Met388 has 3.5 fold lower Kcat, and 3.3 fold higher Km
values when compared to wild type TMEGF45 based on protein C activation assays [94]. It must
also be mentioned that clot stabilizing activation of TAFI by thrombin-thrombomodulin complex
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is unaffected by the oxidation of Met388 [95]. Since the activation of clot stabilizing activated
TAFI, a procoagulant pathway, is unaffected by Met388 oxidation, while activation of protein C,
an anticoagulant pathway, is suppressed by oxidation of Met388, there is no question that
methionine oxidation favors coagulation. Although the effects of oxidation of Met388 on
activation of protein C and TAFI were demonstrated in vitro, it seems likely that oxidation of
Met388 in vivo would lead hemostasis towards coagulation.
Our hypotheses state that the oxidation of methionine 388 in thrombomodulin is higher in
smokers when compared to non smoker. It is our belief that this oxidation is a key molecular
cause of the prethrombotic state in smokers and thus a critical factor in the development of
thrombosis and premature death in smokers. The case for relationship between smoking and
oxidation of thrombomodulin as an important player in cardiovascular diseases has also been
published by the Fernández group [117]. The circulating levels of protein C was compared in
smokers and non smokers, activated protein C was 23% lower in smokers than nonsmokers. One
of the possible causes of low levels of protein C could be due to the reduced thrombomodulin
activity in smokers, probably due to methionine 388 oxidation. We have successfully purified
significant quantities of thrombomodulin from urine from multiple donors, both smokers and non
smokers, and quantified the relative oxidation levels in them.
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Materials and Methods
The University of Arkansas Institutional Review Board approved all experimental
protocols using human subjects. Samples of the first morning urinate were collected by
volunteers in 400 mL centrifuge bottles. Thiodiglycol (5 mL) and 0.5 M EDTA (1 mL, pH 8.0)
were added to containers before sample collection. The collected samples were transported using
an insulated bag containing an ice pack. The samples were generally transported to the
laboratory within two hours of collection and stored at 4°C for no longer than 2 hours before
further processing to minimize the opportunity for oxidation. Typical volumes of the sample
from a donor ranged from 200-550 mL. Prior to processing, 1 mL of sample was removed and
stored in -80°C for determination of the initial thrombomodulin concentration in the sample. The
samples were centrifuged in a Sorvall GS-3 rotor at 4,000 rpm for 30 min at 4°C. The samples
were then filtered using a bottle-top 0.22 µm polyethersulfone (PES) membrane filter to remove
remaining particulates and cellular debris. Sufficient 0.25 M imidazole acetate buffer, pH 6.0
was added to the urine filtrate to bring to a final concentration of 25 mM imidazole acetate. Next,
the pH of the sample was adjusted to 6.0 by addition of 2 M acetic acid or 6 M NaOH depending
on the urine sample. Typically after the addition of 0.25 M imidazole acetate buffer, the pH of
the samples ranged from pH 5.5-6.4.The pH of the sample was measured using a pH electrode. A
slurry of Q Sepharose FF (GE Healthcare) was poured into a 50 mL Bio-Rad Econo column in a
sufficient amount to pack a 20 mL bed volume. A Fluid Metering, Inc (FMI) pump was
connected to the Bio-Rad column to pump buffer and urine sample through the Q Sepharose FF
column at a constant speed of 5 mL/min. The column was first equilibrated with 60 mL of 25
mM imidazole acetate buffer, pH 6.0. Next, the urine sample was passed through the column.
The column was washed with 50 mL of 25 mM imidazole acetate buffer, pH 6.0 and then by
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addition of 20 mL of 25 mM imidazole acetate buffer, pH 6.0, 50 mM NaCl. Fractions
containing thrombomodulin were eluted by addition of 50 ml of 25 mM imidazole acetate buffer,
pH 6.0, 0.5 M NaCl. The 0.5M NaCl fractions were collected in 15 mL conical tubes, 5 mL in
each tube. The eluent after addition of 25 mL of 25mM imidazole acetate buffer, pH 6.0, 0.5 M
NaCl, tested positive for thrombomodulin. A solution of 0.2 M L-methionine (Sigma-Aldrich)
was added to thrombomodulin containing fractions to a final concentration of 2 mM methionine.
The fractions were transferred to 1.5 mL microcentrifuge tubes, typically 14 tubes, and flash
frozen in liquid nitrogen. The frozen eluent in 1.5 mL microcentrifuge tubes was dried under
vacuum in a SpeedVac concentrator system using medium heat.
Reverse phase HPLC purification
The dried samples from ion exchange were pooled and dissolved in minimum volume,
generally 5 mL of total volume, of 18.2 megaohm deionized water. The dissolved sample was
passed through a 25 mm syringe filter with 0.2 µM PES membrane (VWR). The redissolved
sample was injected into a reverse phase Waters HPLC system. An Atlantis dC18, 5 μm particle,
4.6x250 mm column held at 58°C and a 2996 photodiode array detector monitoring 214 nm and
254nm was used. The maximum volume that could be injected into Atlantis dC18, 5 μm particle,
4.6x250 mm column per run is 1.4 mL. The total volume of the sample to be injected into the
HPLC was 5 mL, 4 different HPLC runs had to be performed to purify entire sample. Upon
injection, a gradient was run at 1 mL/min from 10 to 29% acetonitrile, 0.1% trifluroacetic acid
over 12 minutes, and then from 29% to 40% acetonitrile over the next 11 minutes, and then from
40% to 90% acetonitrile over the next 25 minutes. Eluent was collected in 1 mL fractions in 1.5
mL microcentrifuge tubes, to which were previously added 100 uL of 200 mM Tris buffer, pH
8.0. The thrombomodulin containing fragments, identified by ELISA, typically eluted at 30
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minute. Thrombomodulin containing 1.5 mL microfuge tubes were flash frozen in liquid
nitrogen, dried under vacuum in a SpeedVac concentrator system using medium heat. The HPLC
Atlantis column was cleaned using 1.0 mL/min of 90% MeCN/0.1% TFA for 10 minutes,
followed by equilibration for 15 minutes to the starting conditions of 1.0 mL/min of 10%
MeCN/0.1% TFA in preparation for the next injection.
Digestion of thrombomodulin
The dried thrombomodulin containing fractions from the reverse phase chromatography
were pooled and dissolved in approximately 100 uL of 1X phosphate buffered saline (PBS; 1.46
mM KH2PO4, 9.9 mM Na2HPO4, 2.68 mM KCl, 137 mM NaCl, pH 7.4). Based on the previous
attempts with chymotrypsin digestion of thrombomodulin after HPLC purification, we observed
the samples that were cloudy did not undergo digestion with the protease. The samples that were
cloudy prior to digestion were spun in a microcentrifuge (Galaxy 14D VWR) at 13K RPM for a
minute. The supernatant was removed. The precipitate was dissolved in 75 µL of 1X phosphate
buffered saline, and was used for digestion. Freshly prepared tris-carboxyethylphosphine (TCEP)
was added to make the final concentration of 50 mM TCEP. 10 µL of 0.5 M sodium phosphate
buffer pH 7.5 added to the sample, prior to addition of 500 units of PNGase F (New England
Biolabs). The samples were incubated at 37°C for 4 hours to deglycosylate the sample. The
protein was then digested at 30°C for 8 hours after adding 4.1 μg of sequencing grade
chymotrypsin (Princeton Separations) dissolved in 50 mM Tris-HCl, 1 mM CaCl2, pH 8.0. The
chymotrypsin was inactivated by placing the samples in a 100°C dry bath for 30 seconds. The
samples were immediately flash frozen, and stored in -20°C until further processing.
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Mass spectrometry analysis of methionine 388 oxidation
The semi quantification of oxidized and reduced forms of peptide in the chymotrypsin
digested thrombomodulin was conducted by matrix-assisted laser desorption/ionization
(MALDI) mass spectrometry. The MALDI analysis was performed by the Statewide Mass
Spectrometry Facility located at the University of Arkansas. The pure samples were mixed with
the MALDI matrixes. The two types of matrixes used were alpha-cyano-4-hydroxycinnamic acid
(CHCA) and 2,5-dihydroxybenzoic acid (DHB) (Sigma Aldrich). MALDI-TOF mass spectra
were obtained on a Bruker Ultraflex II (Bruker Daltonic GMBH, Bremen, Germany) time-offlight mass spectrometer operated in the positive-ion reflectron mode. The accelerating voltage,
delayed extraction time, and laser power were adjusted to optimize sensitivity and resolution for
ions between m/z 500 – 4000.
UPLC injections of synthetic peptide
The stock solution of the synthetic peptide was diluted using 18.2 megohm water to make
following concentrations: 100, 10, 1, and 0.1 mM. Injections of 25 uL of each of these solutions
were performed on the Waters ACQUITY UPLC system, detector monitoring 214nm. A BEH
130 C18 1.7 µm 2.1x150 mm, reverse phase column heated to 45°C, 0.2 mL/min flow rate was
used to separate the peptide mixture. The eluent was started at 10% MeCN/0.1% TFA and
transitioned to 20% MeCN/0.1% TFA in a linear gradient over two minutes. Over the next 25
minutes, a linear gradient from 20% MeCN/0.1% TFA to 90% MeCN/0.1% TFA was run.
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Results and Discussion
This study was undertaken to quantify the relative oxidation of methionine 388 of
thrombomodulin from smokers and non smokers. Cigarette smoke is a complex mixture of
chemical compounds, including high concentrations of reactive oxygen species and reactive
nitrogen species [12]. Also important is the secondary oxidative stress triggered by ROS and
RNS from cigarette smoke. The lungs of cigarette smoker are exposed to primary and secondary
oxidation from cigarette smoke. Since thrombomodulin is predominantly found in the lungs, we
hypothesize that in smokers it is subjected to significant levels of oxidation from cigarette
smoke.
There are several challenges associated with quantifying the oxidation of
thrombomodulin purified from urine. The thrombomodulin is cleaved into fragments prior to its
circulation in the urine and combined with the heavy mass of the fragments make direct
quantification impossible. Also, the thrombomodulin is heterogeneous in size due to differences
in glycosylation [81, 82]. Peptide mass fingerprinting provides a significantly easier alternative
compared with working with bigger protein fragments. In this technique the protein of interest is
cleaved, and the mass of the resulting fragments is measured using mass spectrometer.
Chymotrypsin digestion of thrombomodulin results in the fragmentation of the protein
into several peptides. Among the peptides of digest, the peptide APIPHEPHRCQMF is the prime
interest for the purposes of this study. This peptide is composed of residues 377-389 of
thrombomodulin. The second to the last methionine residue corresponds to the 388th residue. In
the naturally occurring thrombomodulin this peptide can exist in two different forms;
APIPHEPHRCQMF and APIPHEPHRCQMoxF. The former is a relatively non polar peptide and
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its isotopically averaged mass is 1562.73 Da. The latter is more polar than its counterpart, and its
mass is 1578.74 Da.
Depending on the state of methionine 388 of thrombomodulin, the chymotrypsin
digestion should result in differences in the resulting peptides. If the methionine 388 is
exclusively present in the reduced state, the digestion will only produce APIPHEPHRCQMF. In
the case of methionine completely oxidized to methionine sulfoxide, the digestion results in
exclusive presence of APIPHEPHRCQMoxF. If the methionine 388 is partially oxidized the
resulting digest will have presence of both oxidized and the reduced forms of the peptide. The
presence of either forms of the peptide can be confirmed by MALDI-TOF. The MALDI-TOF
measurement also provides the relative signal intensity of the peptides in the sample. The
intensity of the signal from each peptide is proportional to its concentration in the sample.
Comparing the intensity of different peptides can be problematic though, because each peptide
has a different tendency to ionize and thus be detected. Nevertheless, the intensity of reduced
and oxidized peptide in MALDI-TOF measurement can be used to calculate the approximate
ratio of oxidized and reduced forms of APIPHEPHRCQMF in thrombomodulin. Figure 3.1 is
MALDI-TOF spectra of digested thrombomodulin purified from urine. This urine sample was
collected from a 28 year old male smoker. The intensity of the signal from the reduced peptide
is approximately three fold higher than that of the oxidized form in this particular sample.
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Figure 3.1: MALDI-TOF mass spectra of chymotrypsin digested thrombomodulin purified from
urine. Urine sample was collected from a 28 year old male smoker.
UPLC injections of synthetic peptide
Acquity UPLC offers increased resolution, sensitivity and speed when compared to
HPLC. It uses small particle columns (1.7 µm – 1.8 µm), which improves system efficiency by
producing better resolution, and also lowering the analysis time. This system is designed to
minimize band spreading resulting from the column and also from the instrument. The stock
solution of the synthetic peptide APIPHEPHRCQMF (Sigma) was diluted with 18.2 megohm
water to make 100, 10, 1, and 0.1 mM solutions. The commercial peptide is mixture of both
oxidized and reduced peptides, APIPHEPHRCQMoxF and APIPHEPHRCQMF. 25 uL of each of
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the diluted solutions were injected into the Waters ACQUITY UPLC System. This system is
much more suitable for quantitative analysis than MALDI. The accurate ratio of reduced and
oxidized peptide in each of the solution can be obtained by using the UPLC. The relative area
occupied by the reduced and the oxidized peptide in the UPLC chromatogram can be used to
calculate the ratio of the peptides in each solution. Figure 3.2 is the Acquity UPLC
chromatogram of 25 µL injection of 1 mM synthetic peptide. The ratio of reduced and oxidized
peptide in 0.01 M synthetic peptide solution is 3.26.
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Figure 3.2: Acquity UPLC chromatogram of 25 µL injection of 1 mM synthetic peptide. The
oxidized and reduced peptide elute at 11.2 and 18.7 min respectively. The area occupied by the
oxidized and the reduced peptide is 23.47% and 76.53%. The synthetic peptide purity was >85%,
hence the presence of other peaks in this chromatogram.
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Peptide

Area of reduced

Area of oxidized

Ratio of

concentration(mM)

peak (%)

peak (%)

peptides

100

76.49

23.51

3.25

10

76.46

23.54

3.25

1

76.53

23.47

3.26

0.1

76.58

23.42

3.27

Table 3.1: Ratio of the reduced and oxidized peptides in different concentrations of synthetic
peptide, acquired using a Waters Acquity UPLC.

Table 3.1 shows the ratio of the reduced and oxidized peptide in 100, 10, 1, and 0.1 mM
solutions of the synthetic peptide. The ratio of reduced and oxidized peptide in each solution was
calculated using the relative area occupied by each peptide in the UPLC chromatogram at 214
nm absorbance. Since sulfoxide does not absorb significantly at this wavelength, the amount of
material present in each peak should be directly proportional to the peak areas. In the UPLC
chromatogram of 100 mM synthetic peptide, the reduced and oxidized peptide occupied 76.49%
and 23.51% area respectively. Based on that information, the ratio of reduced and oxidized peak
in the 100 mM solution was calculated to be 3.25. The mean ratio for the four different solutions
was 3.25 with a standard deviation of 0.01.
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We attempted to use Acquity UPLC to directly quantify the oxidation of methionine 388
of thrombomodulin purified from urine. The synthetic peptide mixture was injected into the
UPLC to map the peptide. Under these conditions, the oxidized and reduced peptide elute at 12
and 21 min respectively (Figure 3.3).
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Figure

3.3:

Acquity

UPLC

chromatogram

of

the

commercial

peptide

APIPHEPHRCQM(ox)F elutes at 12 min and APIPHEPHRCQMF elutes at 21 min.
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mixture.

The chymotrypsin digested urinary thrombomodulin was injected into the UPLC system.
Unfortunately, there were several contaminating peptides that eluted very near or even co-eluted
with the peptide of interest. Despite trying numerous elution profiles, the resolution necessary to
calculate the relative area occupied by the oxidized and the reduced peptide often could not be
achieved using the UPLC. The digested samples had slightly different elution times from the
synthetic peptides and co-injected samples had slightly different elution times still. These
problems were exacerbated when of the two peaks was only minimally present. It was, in those
cases, difficult to be sure which peak was the one of interest. It is possible that a good UPLC-MS
system could overcome these difficulties, but attempts to interface our UPLC directly with a
mass spectrometer failed because none of the mass spectrometers available to us had high
enough scan rates. Peaks were often not detected by MS. The use of UPLC to calculate the
methionine oxidation was therefore discarded.
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Figure 3.4: UPLC chromatogram of chymotrypsin digested urinary thrombomodulin of a 26 year
old Caucasian male non smoker. The two forms of peptide elute at 12 and 21 min respectively,
notice the contaminating peaks at those times.
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Figure 3.5: Overlay of UPLC chromatograms. Top chromatogram is of chymotrypsin digested
urinary thrombomodulin of a 26 year old Caucasian male non smoker, and the bottom
chromatogram is of synthetic peptide mixture.
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Accuracy of quantification by MALDI
Matrix-assisted laser desorption ionization (MALDI) is a powerful technique for mass
spectrometry of peptides and proteins [178]. This technique provides fast and accurate
acquisition of molecular mass and purity. Some of the advantages offered by this instrument are
follows: It is very easy to operate and it is tolerant towards the presence of buffers, salts and
other additives. It can be used for analysis of compounds with a MW over 300 KDa [199]. It
ionizes the analytes very softly; usually only M+H+ and a small amount of M+2H+ ions are
generated making analysis of mixtures feasible. Briefly, solution of analyte is mixed with the
matrix (2,5-dihydroxybenzoic acid) directly on a target, and evaporation produces crystals which
are a mixture of the analyte and matrix. The laser UV pulse is directed on the matrix/analyte
crystals, matrix ionizes and transfers charge to the analyte, and the ionized matrix and analyte
vaporize and expands into gas phase. Despite its popularity with analysis of proteins and
peptides, this technique is considered impractical for the analysis of analytes that have low mass
and for quantitative analysis [200]. The presence of excess matrix can blanket the low m/z signal
in the spectrum that corresponds to the analyte with low mass.
Quantitative analyses are not generally attempted in MALDI because there is not a
uniform distribution of the sample and the matrix on the surface of the target. This creates a
variability of the analyte within the matrix, and as a result there is significant variability in the
peak intensities, baseline, and noise level seen in MALDI spectra from the same sample [200].
Another challenge in conducting quantitative studies of complex sample using MALDI is the
competitive ionization and ion suppression. Some analytes have greater affinity for charge than
others and they are more competitive in obtaining available proton. For example, peptides that
terminate in arginine have higher affinity in charge when compared to peptide that ends with
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lysine [201]. However, for our purposes the difference in ionization efficiency of different
components in the sample is less important, since we are only interested in two versions of a
single peptide. Also, to enhance the quantitative ability of MALDI, alpha-cyano-4hydroxycinnamic acid (CHCA) was used as a matrix to produce an ultrafine homogenous
sample-matrix composition. It showed better sensitivity and reproducibility compared to
traditional dried droplet preparations using 2,5-dihydroxybenzoic acid (DHB) [202, 203].
The accuracy and the precision of MALDI-TOF can be directly tested using synthetic
peptide APIPHEPHRCQMF. The commercial peptide is mixture of both oxidized and reduced
peptides, APIPHEPHRCQMoxF and APIPHEPHRCQMF. The stock peptide was diluted using
18.2 megohm water to prepare 100, 10, 1, and 0.1 mM solution of the synthetic peptide. These
solutions were sent for MALDI analysis. For each sample, three different sample-matrixes were
prepared, and each of the sample/matrix was subjected to approximately 5000 shots. Table 3.2
shows averaged intensity values from these 5000 shots for reduced and oxidized peptide in 100,
10, 1, and 0.1 mM solutions of the synthetic peptide. MALDI of 1 µL (5 pmol) of 0.01 mM
synthetic peptide did not produce a detectable signal for oxidized peptide.

95

Peptide

Ratio of
Intensity of Reduced

Intensity of Oxidized

Peptide (A.U)

Peptide (A.U)

concentration

Intensities

(mM)

(red/ox)

100

14000

1000

14

10

12500

1500

8.3

1

5400

1000

5.4

0.1

2300

250

9.2

Table 3.2: The average MALDI spectra intensities of reduced and oxidized synthetic peptide in
four different solutions. Three sample-matrixes were mixed for each solution, and each samplematrix was subjected to approximately 5000 shots. The table provides average values from these
shots (A.U = arbitrary units). The fourth column is the ratio of the second and the third column.
MALDI of 1 µL of 0.01 mM solution of peptide did not produce a signal for oxidized peptide.
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The 100, 10, 1, and 0.1 mM solutions of the synthetic peptide were prepared by serial
dilution of the stock solution of the synthetic peptide. The ratio of reduced and oxidized peptides
in each of the solutions should be same even after the dilutions. The fourth column on Table 3.2
provides the ratio of the two forms of peptides in each of the solutions, the mean of the ratios is
9.2, and standard deviation is ± 3.6. Clearly, the Acquity UPLC system is much more suitable for
quantitative analysis compared to MALDI and, when it was used to measure the mean ratio of
reduced and oxidized peptide in each solution (Table 3.1), the calculated mean was 3.25. With
such low accuracy and precision, the use of MALDI for quantification of two forms of peptide in
a sample is challenging. MALDI overestimates the amount of the reduced form and the
measurement is much more variable. However, if the differences in thrombomodulin methionine
388 oxidation in cigarette smokers and non smokers are large enough, these weaknesses do not
prevent detection of dissimilarities.
Relative methionine oxidation in smokers and non smokers
There are a few definitions we use to classify our donors. A cigarette smoker is someone
who has been smoking for at least the past six months, smokes a minimum of 5 cigarettes per
day, and does not smoke anything other than tobacco (e.g. marijuana). A non-smoker is
someone who has not smoked in over six months and does not use any other form of tobacco and
is not heavily exposed to secondhand smoke. A never-smoker is a non-smoker that has never
smoked. A secondhand smoker is an otherwise non-smoker who is heavily exposed. A former
smoker is someone who has not smoked for least six months.
We wanted to minimize the variables that are linked with oxidation in this research. For
example, a donor who has diabetes would be under increased oxidative stress, and such condition
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would increase the uncertainty of our results. The donors were carefully screened to eliminate
the ones who could be under greater oxidative stress than normal. Potential donors with known
history of cardiovascular diseases, diabetes, high blood pressure, hyperhomocysteinemia, severe
arthritis, renal failure, current use of anti-coagulants, recent surgery, extreme use of over-thecounter anti-oxidant vitamins, chronic allergies or infection, and pregnancy were excluded from
this study.
In this study a smoker donor was matched with non-smoker control, and the difference in
methionine 388 oxidation between the two was measured. It was very important to minimize the
variables that affect oxidation in the smoker and the control. In our study smokers were matched
with controls based on age, gender, and race. We understand that the oxidation of
thrombomodulin could be affected by multitude of factors such as diet, differences in expression
of repair proteins, variability in expression of thrombomodulin, and many other possibilities, and
it would be impossible to eliminate all variables between the smokers and the control.
The oxidation of methionine 388 of thrombomodulin was studied in six non smokers (Table 3.3)
and 13 smokers (Table 3.4). In the two out of six non smokers the MADLI spectra did not report
the presence of oxidized peptide. The average ratio of reduced and oxidized peptides in four non
smokers was 1.5. The concentration of reduced peptide was higher. Conversely, six of the
thirteen smoker subjects did not have reduced peptide in the MALDI spectra (Table 3.4). The
average ratio of reduced and oxidized peptide for the seven smokers was 0.58. The ratio of
oxidized peptide was higher in cigarette smokers. The reduced/oxidized ratio and percent
oxidation in Tables 3.3 and 3.4 must not be taken literally. We know that MALDI tends to either
overestimate the level of reduced peptide or underestimate the level of oxidized peptide or some
combination of both. In other words both non-smokers and smokers are likely to be actually
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much more oxidized than the values in the two tables indicate. However this systematic error is
similar for both populations. While we cannot say exactly how much the oxidation levels differ,
we can examine whether the differences observed are statistically significant.
The presence of completely reduced peptides in two non smokers, and presence of
completely oxidized peptide in six smokers and the relative ratio of the two forms of peptides in
smokers and non smokers clearly indicate that the methionine 388 of thrombomodulin in
cigarette smoker is significantly oxidized in smokers. In order to perform the t-test, we revisited
each of the MALDI spectra of digested thrombomodulin and recorded the noise level. The noise
level was multiplied by the factor of 2.5. This value was assigned for the peptide which was not
detected in the MALDI spectra. This, of course, is a very conservative estimate for the amount
of the peptide that was not detected and most of the actual values are likely much less than this.
The ratio of the reduced to oxidized peptide MALDI data from smokers and non smokers passed
the Shapiro-Wilk test for normality (P=0.068) and an equal variance test (P=0.111). Statistical
comparisons were performed using Student's t-test (t= 3.72, P=0.001). Thus, there is a very
statistically significant difference between thrombomodulin methionine 388 oxidation in
smokers and non smokers, despite using very conservative estimates.
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Figure 3.6: MALDI-TOF spectra of chymotrypsin digested urinary thrombomodulin of 25 year
old caucasian male never smoker (Donor code: NS 36, Table 3.3). The spectrum shows presence
of both reduced and oxidized peptides. The signal to noise ratio is greater than 10 for both forms
of peptide.
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Donor Code Red (A.U) Ox (A.U) Red/Ox Age Gender Race Smoker Noise (A.U) % Oxidation
0.25
5
Never
C
M
52
3.1
30
92
NS 02
0.60
8
Never
C
F
32
0.7
18
12
NS 11
< 0.28
130
Never
C
M
24
2.5
< 325
812
NS 23
< 0.47
35
Never
C
M
30
1.1
< 87.5
98
NS 28
0.44
8
Never
C
M
25
1.3
14
18
NS 36
0.51
51
C Non, 4 years
M
28
0.9
99
94
NS 40

.

Table 3.3 : MALDI spectra values of oxidized and reduced peptides in non smokers. NS = Non

smoker, ND = Not Detected, Red = Reduced, Ox= oxidized, A.U. = arbitrary units, M = male, F

= female, C = Caucasian
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Table 3.4: MALDI spectra values of oxidized and reduced peptides in cigarette smokers. CS =

cigarette smoker, ND = not detected, Red = reduced, Ox= oxidized, M = male, F = female, A.U

= arbitrary units, C = Caucasian, SEA = South East Asian. Daily intake is the number of

cigarettes smoked per day. Noise is the background noise of the spectra. % oxidized is the

percentage of oxidized peptide.
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Donor Code Red (A.U) Ox (A.U) Red/Ox
CS 19
< 25
1150
0.02
CS 116
< 7.5
141
0.05
CS 119
550
1775
0.31
CS 123
< 325
522
0.62
CS 126
1105
3592
0.31
CS 132
83
254
0.33
CS 134
78
56
1.39
CS 135
14
43
0.33
CS 137
29
43
0.67
CS 138
< 62.5
67
0.93
CS 139
20
131
0.15
CS 140
< 12.5
60
0.21
CS 141
< 12.5
59
0.21

Age
29
39
22
60
23
38
26
35
19
21
32
45
27

Gender Race
M
SEA
M
C
M
C
M
C
M
C
F
C
F
C
M
C
M
C
M
C
M
C
M
C
M
C

Smoker Daily intake Noise (A.U) % Oxidized
8 yr
10
10
> 0.97
10 yr
14
3
> 0.95
2.5 yr
7
90
0.76
30 yr
7
130
> 0.62
3 yr
7
90
0.76
15 yr
12
55
0.75
4 yr
11
15
0.42
20 yr
20
8
0.75
1 yr
2
9
0.60
2 yr
6
25
> 0.52
3 yr
5
9
0.87
15 yr
9
5
> 0.83
2 yr
7
5
> 0.83

It is necessary to consider what the effects are of assuming that the amount of any peak
that is not detected is equal to 2.5 times the noise level. Again, this is a conservative assumption
that has the effect of making the average non smoker seem more oxidized and the average
smoker less oxidized. This moves the two averages toward each other, but also tends to make
them more normally distributed. If we assume that the peak that is not detected is present in the
same amount as the noise level (data not shown), the data are no longer normally distributed,
failing the Shapiro-Wilk test. However, using the non-parametric Mann-Whitney Rank Sum test
we discover, unsurprisingly, that the difference in the median values of the two groups (Red/Ox
median non smoker 2.043; smoker 0.308) is still greater than would be expected by chance
(P=0.002).
In a few cases a peak was detected which was greater than the noise level but not 2.5
times larger. We examined the effect of excluding these individuals entirely if both peaks were
below this cut-off while if just one of the two peaks was detected, but below 2.5, increasing it to
2.5 the noise level. The data passed the Shapiro-Wilk test (P=0.516) but failed the equal
variance test, presumably because only three values were left for the non smokers. However, the
Mann-Whitney test still showed that the difference (Red/Ox median non smoker 2.498; smoker
0.310) between the two groups was quite significant (P=0.015). Clearly, there is a stastically
significant difference between the two populations.
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Possible Future Work
In the future we would like to expand this study to greater numbers of participants to
determine how oxidation varies for the many permutations of smoking behavior. We plan to
recruit smokers with a wide range of cigarette consumption habits. We expect a relationship
between higher levels of smoking and higher oxidation, and our hypothesis would be further
supported if we can establish there is a dose dependent curve. While conducting this study, we
expect some donors to display variably that would not be consistent with dose dependent curve.
Determining the degree to which there is variability which is not explained by the amount of
smoking is very important. It is possible that some individuals resist the oxidation of
thrombomodulin better than others. This could be due to multitude of factors some of which
could be diet, environment, differential expression of repair proteins, and differential expression
of thrombomodulin. Identification of such individuals offers extension of this research project.
Firstly, we would identify the factors that make them vary from normal smoking behavior. Next
steps would be identifying how influential individual factors are by themselves, and eventually
their effects in myriad permutations and combinations.
Pipe and cigar smokers typically do not inhale the smoke, and that differentiates them
from cigarette smokers. We are interested to see how pipe and cigar smoke affects
thrombomodulin. Since these smokers typically do not inhale the smoke this offers a very useful
avenue for testing the hypothesis that the bulk of thrombomodulin oxidation in cigarette smokers
is localized to the lungs. It would be informative to recruit smokeless tobacco users, and
compare the thrombomodulin oxidation levels.

104

The American Heart Association has concluded that passive smoking is an important risk
factor for heart disease in both adults and children [204]. AHA estimates 22,700 to
69,600 annual premature deaths from heart and blood vessel disease are caused by passive
smoking [205]. We would like to examine the effects of secondhand smoke on non-smokers, by
recruiting donors who live with smokers or donors working in a bar. It is difficult predict
whether we will be able to detect a measurable, and statistically significant oxidation in
secondhand smokers, but in light of our research findings, we believe it will be worthwhile to
quantitate thrombomodulin methionine oxidation in second hand smokers. The degree of
cigarette smoke is measured by counting the number of cigarettes smoked in a day, however for
the second hand smoke study we need a quantitative test to record cigarette smoke inhaled by the
donor. The self reported method by the non smokers are going to be inaccurate due to multiple
factors some of which are proximity of nonsmokers to smokers, ventilation of the room, and
individual differences in exposure sensitivity. Nicotine would be an ideal biomarker for this
study, however it has a half life of 2 hours making it unsuitable [206]. Nicotine from tobacco
smoke when taken into the lungs enters into the bloodstream. When nicotine in the blood stream
reaches liver it is processed into cotinine, which is the principle metabolite of nicotine from
tobacco smoke. Cotinine and has been documented to be a sensitive and specific marker for
tobacco exposure [207]. It is found in saliva, plasma and urine [208]. Urinary cotinine
concentration has been shown to be accurate biomarker for tobacco exposure [208-210]. The
degree of cigarette smoke exposure of the passive smoker can be measured using cotinine
ELISA. The thrombomodulin methionine 388 oxidation is passive smokers can be studied using
our current protocol combined with cotinine as a biomarker.
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The MALDI spectra of chymotrypsin digested thrombomodulin from non smokers and
smokers gave us insight into methionine 388 oxidation. We have established that methionine 388
of thrombomodulin in smokers is more oxidized, and we propose that the oxidation of
methionine 388 in thrombomodulin could be one of the key molecular causes for cardiovascular
diseases in cigarette smokers. The immediate extension of this research would be to find
treatment that would reduce the oxidized methionine 388 of thrombomodulin. Since cigarettes
are the ones imposing oxidative stress the first step towards treatment would be for a smoker to
quit smoking cigarettes. We could set up an experiment where a smoker is willing to quit
smoking. The urine samples will be collected at frequent intervals before and after the donor
quits. The samples would be collected for six months from the date the smoker quits smoking,
with cotinine tests to verify abstinence. The MALDI data collected over that span will be
analyzed to see if there are any changes to the oxidation levels of methionine. We speculate that
the oxidation levels to decrease. Six months ago we found a donor who volunteered to quit
smoking cigarettes for this study. Urine samples were collected for a span of 1 month before the
donor quit smoking, and samples have been collected at a frequency of 3 weeks interval. The
urine samples have undergone reverse phase HPLC step of purification, and are currently stored
in -20˚C. When the donor completes 6 six months without smoking, the stored samples will be
subjected to chymotrypsin digestion and will be sent for MALDI analysis. We are actively
looking for donors who plan on quitting smoking. In the past few months we have found three
donors who planned on quitting, and two of them did quit, but only for the span of 1-2 weeks.
We could approach smoking cessation clinics to recruit smokers trying to quit. The state of
Arkansas has chosen to use some of its tobacco settlement money to subsidize the cost of
clinically proven programs, which means that there are a number of fairly popular and successful
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programs working in the area. Experiments where many permutations of donors who quit
smoking could be designed based on age, sex, race and degree of smoking, and compare each
factor towards recovery. For comparison, if we could find a donor who intends to pick up
smoking would provide us insight on rate at which cigarette smoke oxidizes methionine 388 of
thrombomodulin.
Annually 437,900 people are killed by diseases caused by smoking, and 35% of those
deaths are cardiovascular related [20]. Cigarette smoke is the major cause of pulmonary
emphysema [21], bronchitis, myocardial infarction, and stroke as well as lung cancer. Four
million people die every year from tobacco smoking related diseases worldwide. It has been
estimated that 2 billion people use tobacco products [22]. Approximately 64.5 million people in
the USA are active smokers, between 1995-1999 the estimate of deaths that resulted from
smoking and exposure to secondhand smoke was approximately 440,000 annually [23]. Cigarette
smoking ranks number one in the list of preventable disease and death worldwide. In 2004,
cigarette smoking cost the United States over $193 billion, this number includes $97 and $96
billion from loss in productivity and in direct health care expenditures respectively [211]. The
average cost to the government was $4,260 per adult smoker [211]. As we have mentioned
previously, we propose methionine 388 oxidation is one of the key molecular mechanism for
development of cardiovascular diseases in smokers. Treatment to mitigate or regress methionine
388 oxidation in smokers has potential to minimize or prevent morbidity and fatality in cigarette
smokers. We could design experiments where mice are subjected to cigarette smoke for a period
that would induce cardiovascular like symptoms. Following the development of disease, they are
treated with antioxidants like apocynin or Tempol [212-214], and the effectiveness of the
antioxidants is monitored.
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Prolylcarboxypeptidase (PRCP) is an endothelial membrane-bound serine
carboxypeptidase responsible for activation of bradykinin and angiotensin [103-105]. Both
proteins regulate the vascular NO to provide protection from thrombosis. PRCP is indirectly
involved in maintenance of normal blood pressure and reduction of thrombosis risk. PRCP
polymorphism has been associated with hypertension and inflammation [106]. PRCP genetrapped mice are hypertensive and are prone to faster thrombosis [107]. These mice have
increased in vivo vascular ROS and uncoupled endothelial nitric oxide synthase (eNOS) and
reduced expression of vascular thrombomodulin in their aorta [108, 110]. The hypertensive and
prothrombotic state in PRCP gene trapped mice was abrogated by antioxidant treatment using
mitoTEMPO, apocynin, and Tempol [107]. The paper demonstrates that the hypertensive and
prothrombotic state arose from high levels of ROS in PRCP gene trapped mice, and this state
was reversed by antioxidant treatment. The potential of antioxidants treatment in cigarette
smokers to suppress smoking related cardiovascular disease is worth exploring.
Shifting from urinary thrombomodulin, we are also interested in plasma thrombomodulin.
The level of plasma thrombomodulin has been associated as an indicator of endothelial damage
in patients with disseminated intravascular coagulation syndrome, pulmonary thromboembolism,
adult respiratory distress syndrome, chronic renal failure, acute hepatic failure, atherosclerosis
[121, 215-217]. In one study, plasma thrombomodulin concentrations of smokers and non
smokers were studied [218]. They found the plasma levels of cigarette smokers was 15% lower
than the mean. We would like to see if there is any correlation between the concentration of
plasma thrombomodulin and methionine 388 oxidation in cigarette smokers.
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Conclusion
We have shown that methionine 388 is significantly more oxidized in smokers than nonsmokers. Oxidative damage to the endothelium from the oxidants in cigarette smoke has been
suggested to be an important factor for the development of cardiovascular diseases in smokers.
Smokers are in a hypercoagulable state, but this is the first evidence for a specific molecular
origin of this state. Methionine 388 oxidation has been shown in vitro to have large effects on the
activity of the thrombomodulin. The mutation of thrombomodulin methionine 388 to any other
residues, except leucine, decreases the anticoagulant cofactor activity of thrombomodulin [91].
More importantly, there is 76-90% loss of activity when Met388 is oxidized [92]. We believe
oxidation methionine 388 of thrombomodulin is one of the key molecular causes of the
prothrombotic state in smokers and thus a critical factor in the development of thrombosis and
premature death in smokers. In this chapter we have shown a method allows the semi
quantitative analysis of methionine 388 oxidation in the thrombomodulin isolated from urine
sample. This method offers a useful way to compare thrombomodulin oxidation in cigarette
smokers and non smokers. In this study we report that methionine 388 of thrombomodulin is
more oxidized in cigarette smokers than in non smokers, and we propose that one of the
molecular causes for prethrombotic state seen in smokers is from oxidation of methionine 388 of
thrombomodulin.
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